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1. INTRODUCTION  
  
1.1 General aspects of immunology 
Our immune system protects us against and enables our coexistence with the numerous 
infectious microorganisms inhabiting the earth. A complex network of specialized cells, 
molecules, proteins and organelles comprises the immune system, which we generally 
divide into an innate and an adaptive arm1. The innate immune system provides the first 
line of defence against invading pathogens and provides immediate protection in a non-
specific manner. One critical event in innate immunity is the inflammatory response, 
which is initiated by tissue resident macrophages upon their initial encounter with 
infectious agents. The release of cytokines and chemokines activates the vascular 
system and the complement system and attracts other leukocytes essential in the 
clearance of the infection. In addition to initiating inflammatory responses and 
controlling commencing infections, one of the most important tasks of the innate 
immune system is the priming and activation of the adaptive response. Professional 
antigen presenting cells (APCs) play a key role in this process. APCs engulf pathogens 
at the site of entry and subsequently travel via the lymphatic system into draining lymph 
nodes. APCs mature and acquire the ability to efficiently communicate with T 
lymphocytes, specialized cells of the adaptive response, which are encountered in high 
numbers in the lymph node. The APC presents processed antigen on major 
histocompatibility complex (MHC) molecules on the cell surface to T cells and enables 
a highly specific response against a single antigen with a resulting clonal expansion of 
the responding T cell. Activated T cells upregulate adhesion and costimulatory 
molecules, allowing efficient interaction with B cells sensitized to the same antigen. 
Clonal expansion of antigen specific T cells and B cells forms the basis for 
immunological memory, a unique feature of the adaptive immune system, which refers 
to the ability to “remember” a specific antigen such that on a second encounter a much 
faster and more efficient immune response is mounted. 
 
The ability to mount a specific immune response against an ever-changing infectious 
environment while preventing immune responses against self, which is also subject to 
constant change, is a critical feature of the immune system. An unrestrained immune 
response against self-proteins can lead to tissue damage and autoimmune disease. To 
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prevent this, tight communication between the innate and the adaptive immune system 
as well as the tissue in question is warranted. The mechanisms in control are not fully 
understood, but rely on a conserved ability to distinguish between self and non-self 
combined with the release of specific danger signals2-4. 
 
1.1.1 T cells  
T cells arise from the bone marrow and migrate to the thymus where a maturation and 
selection process takes place. The T cell recognizes antigen through a membrane bound 
heterodimeric T cell receptor (TCR) composed of an  and  chain (TCR) or a  and 
 chain (TCR). The receptor genes are encoded by variable (V), diversity (D) and 
joining (J) gene regions. In a process known as V(D)J recombination the receptor genes 
undergo somatic recombination events which create the vast receptor repertoire of 
mature T cells. T cells are divided into T helper (h) cells and cytotoxic T cells and the 
TCRs recognize antigens as peptide fragments bound to self-MHC molecules. Th cells 
express the cluster of differentiation (CD) 4 coreceptor and recognize peptides on MHC 
class II molecules. Peptides loaded on MHC class I molecules are recognized by 
cytotoxic T cells bearing the CD8 coreceptor. A positive and negative selection process 
in thymus, which depends on presentation of self-proteins on self-MHC molecules by 
thymic epithelial cells and thymic dendritic cells (DCs), defines the repertoire of 
circulating T cells5-7. While positive selection ensures survival of T cells that express a 
receptor with moderate affinity for self-peptides, negative selection eliminates T cells 
with a receptor that binds too strongly to self-peptides. Naïve T cells leave the thymus 
and migrate to secondary lymphoid tissues where they may encounter activated APCs.  
 
Peripheral DCs capture antigen at the site of infection and subsequently migrate to 
secondary lymphoid organs. DCs, macrophages and B cells are termed professional 
APCs due to their expression of MHC class II molecules and their ability to present 
peptides to and activate naïve CD4+ T lymphocytes. DCs are the most efficient APC 
and express high levels of MHC molecules in combination with costimulatory 
molecules, which are necessary for the activation and clonal expansion of naïve T cells. 
Upon antigen recognition, a tight interface, referred to as the immunological synapse, is 
formed between the T cell and the APC8. Thousands of TCRs in combination with CD4 
or CD8 coreceptors are found in complex with peptide-bound MHC molecules clustered 
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in the middle of the synapse. Costimulatory molecules such as leukocyte functional 
antigen (LFA)-1, integrin and CD28 engaging the APC ligands, intracellular adhesion 
molecule (ICAM)-1 and B7, respectively, form an outer rim of the synapse. A fine 
balance between positive and negative signals delivered during the T cell-APC 
interaction decides the fate of the T cell9,10. In the absence of adequate costimulation a T 
cell may become anergic or die, whereas adequate stimulation leads to activation. 
Depending on the nature of activating signals and cytokines secreted by the APC, an 
antigen specific CD4+ T cell may differentiate into one of several subsets of Th cells. So 
far, three major subsets have been identified: Th1, Th2 and Th17, each with different 
effector functions. Although no such classifications subdivide CD8+ T cells, various 
effector functions have been described for phenotypical subsets of CD8+ T cells11.  
 
Upon clonal expansion, one naïve T cell can give rise to approximately 1000 daughter 
cells of identical specificity that further differentiate into effector and memory T cells. 
Effector T cells upregulate cell adhesion molecules, such as ICAM, vascular cell 
adhesion molecule (VCAM), LFA-1 and 41-integrin, and chemokine receptors that 
allow attraction and migration into sites of inflammation. The life span of effector T 
cells is short and the majority will die by apoptosis during the immune response. A 
proportion of the activated T cells differentiate into memory T cells, which persist after 
the removal of antigen and form the basis for T cell memory. Alterations in the 
expression of several surface molecules differentiate memory T cells from naïve cells 
and confer enhanced survival, higher antigen sensitivity, directed migration to tissues 
instead of lymphoid organs and increased adhesion to APCs and endothelial cells12. 
 
1.1.2 B cells  
B cells develop from haematopoietic stem cells in the bone marrow through the process 
of B cell lymphopoiesis. Membrane bound immunoglobulin (Ig) serves as the antigen 
specific B cell receptor (BCR) and can be secreted as an Ig molecule by B cells which 
have differentiated into plasma blasts and plasma cells13. A monomeric Ig molecule 
contains two identical light (L) chains and two identical heavy (H) chains, each with a V 
and a constant (C) region. The H chain determines the isotype and thereby the effector 
functions of an antibody molecule and comes in five main isotypes: IgM, IgD, IgG, IgA 
and IgE. L chains can either be kappa () or lamda (). The antigen-binding site is 
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formed by pairing the V domains of the H and L chains. This results in a surface 
complementary to a specific antigen, with three highly variable loops termed the 
complementarity determining regions (CDRs), interspaced by three framework regions 
(FRs)14. The diversity of the Ig repertoire in naïve B cells is generated by stochastic 
recombination of the Ig H (V,D,J) and the Ig L (V,J) chain loci, similar to the 
development of the TCR. Once a functional BCR is expressed, the specificity of this 
receptor is tested15. B cells with a receptor that recognizes self-molecules will either be 
eliminated from the repertoire, become anergic or ignorant or undergo receptor editing. 
The process of receptor editing involves replacement of the L chain, which will 
combine with the existing H chain, and change the antigen specificity of the receptor. If 
the new receptor is not self-reactive, the B cell is rescued from apoptosis. Naïve B cells 
with a functional receptor migrate to secondary lymphoid organs where further 
maturation takes place through antigen recognition and T cell help.  
 
The activation and differentiation of a naïve B cell into an antibody secreting cell 
requires two signals; one signal is provided through the BCR upon antigen binding, the 
other signal is usually provided by an armed CD4+ T cell which recognizes fragments 
from the same molecular complex presented by MHC class II molecules on the surface 
of the B cell. An important part of this interaction is expression of the B cell stimulatory 
molecule CD40 ligand on the T cell surface, and the secretion of stimulatory 
cytokines16,17. The ensuing T-B cell collaboration, which takes place at the border 
between the T cell and B cell zones in secondary lymphoid organs leads to rapid 
expansion of both B and T cells. A proportion of the activated B cells form germinal 
centers where several modifications of the B cells are induced18,19. This includes isotype 
switching where the gene segment encoding the V region reshuffles to another C gene, 
maintaining the antigen specificity while providing a new C region with a suitable 
effector function. Subsequently, the rearranged BCR V gene segment undergoes 
hypermutation at a rate that is at least 103-104 fold greater than the normal rate of 
mutations across the genome20. When these hypermutated BCRs are “tested” against the 
antigen, B cells having achieved better affinity will be positively selected, while B cells 
with lost affinity will die from apoptosis. This ongoing process is referred to as affinity 
maturation and ensures selection of B cells with the highest affinity. B cells differentiate 
into antibody secreting plasma cells or into memory B cells. Memory B cells upregulate 
MHC class II molecules and costimulatory molecules enabling a highly efficient 
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response upon a second encounter with the antigen. Some plasma cells migrate back to 
the bone marrow where they provide a source of long-lasting, high-affinity antibodies. 
The mechanisms maintaining serological memory is poorly understood but may in part 
depend on polyclonal activation of memory B cells21. 
 
1.2 Idiotopes and anti-Id responses 
The ability of the immune system to mount a highly specific response against the 
diverse antigenic determinants present in our environment relies on the process of TCR 
and BCR rearrangement as well as affinity maturation of the B cells. This creates 
unique protein sequences that are not encoded by germline genes and can themselves be 
perceived by the immune system as immunological non-self, antigenic determinants. 
This forms the basis for the description of idiotopes (Ids), which are clonally unique 
antigenic determinant located in the V region of BCRs and TCRs22,23. One receptor 
carries several Ids, which collectively are referred to as the idiotype of that receptor. In 
1974 Niels K. Jerne postulated the presence of an immunologic regulatory network 
based on anti-idiotopic antibodies, which later won him the Nobel Prize24. Jerne’s 
theory included only Ids located in BCRs and can be illustrated by the following 
example: antibody (Ab) 1 binds an antigen. Ab2 binds the Id of Ab1 and is thereby an 
anti-idiotypic antibody. Ab2 displays a structural resemblance to the antigen and is 
therefore an internal image of the antigen. Ab2 could thus play a key role in 
immunological memory, preserving the epitope of encountered antigens and at the same 
time serve a regulatory role by immobilizing Ab1 and inhibit the immune response to 
the antigen. This type of B lymphocyte regulation was suggested to be partially 
responsible for preventing an uncontrolled immune response24.  
 
1.2.1 T cells in idiotypic networks 
In Jerne’s original network theory only antibodies and B cells were included, but it has 
since become clear that also T cells can participate in Id-driven regulatory networks25,26. 
Studies on Id-specific T cell responses have been facilitated by Ids expressed by plasma 
cell tumors27. Mice immunized with myeloma protein were shown to develop protective 
antibody responses against Ids and suppressed growth of the corresponding transplanted 
tumour cells28. The anti-Id response was suggested to be T cell dependent because T 
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cell deficient mice did not produce anti-Id antibodies upon immunization29,30. 
Additional evidence for the existence of Id-specific T cells was demonstrated in 
adoptive cell transfer experiments25.  
 
By employing a similar assay system, the target of an Id-specific T cell response was 
mapped to the 2 Id located to the BCR L chain, and the immune response was shown 
to be controlled by MHC linked genes31,32. Three somatic mutations present in the VL 
region were found to be critical for the T cell response33. This system has been used to 
further investigate Id-specific T cell responses in cancer surveillance and autoimmunity. 
CD4+ T cells specific for the 2 Id were shown to protect against a MHC class II 
positive and a MHC class II negative tumour, which both secreted the 2 Id34. This 
suggested that the 2 Id was processed and presented on MHC class II molecules by 
host APCs, which in turn could activate Id-specific T cells. This finding was principally 
important considering the tendency of tumours to down-modulate MHC class II 
molecules, and supported by the observation that DCs surrounding the tumours were 
loaded with tumour antigens and could activate tumour-specific CD4+ T cells35. These 
observations have paved the way for strategies involving Id-based vaccination against 
tumour development36. Several of these have been successfully applied in animal 
models and may hold promise for cancer treatment in humans.  
 
As demonstrated in experimental autoimmune encephalomyelitis (EAE), Ids present in 
TCRs of pathogenic T cells may also hold therapeutic potential. Immunization with 
attenuated encephalitogenic T cells has been shown to protect mice against disease 
development37. The clinical effect was associated with the activation of T cells specific 
for Ids located in the TCR of encephalitogenic T cells, suppressing their pathogenic 
potential38. This has led to clinical trials in multiple sclerosis (MS) patients39. Patients 
vaccinated with expanded autologous myelin specific T cells have consistently 
demonstrated a reduction in T cell reactivity to myelin and a concomitant positive 
clinical effect has been observed in some patients40-42.  
 
1.2.2 Id responses in autoimmunity 
The relevance of Id-specific responses in the development of autoimmune disease can 
be demonstrated in experimental models of systemic lupus erythematosus (SLE). SLE is 
associated with strong autoantibody responses against DNA and nuclear proteins43 and 
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the majority of SLE patients develop anti-idiotypic antibodies against common Ids 
present in the VH chain of anti-DNA autoantibodies44,45. Experimental SLE can be 
induced in naïve mice of different strains following immunization with anti-DNA 
autoantibodies or with Id-peptides present in the H chain of these antibodies44,46. Prior 
to clinical disease lupus prone mice spontaneously develop polyclonal T cell responses 
to Id-peptides, suggestive of in vivo processing and presentation of autoantibodies on 
MHC molecules47. Two important observations underscore the relevance of T cell 
responses to Id in experimental lupus. First, adoptive transfer of Id-specific T cells is 
shown to accelerate disease48,49 and, second, amelioration of disease can be achieved by 
the induction of T cell tolerance to Id-peptides47,50,51. This was done by weekly 
intravenous injections of Id-peptides in the absence of adjuvant and was associated with 
induction of an anti-inflammatory phenotype of responding T cells displaying a 
decrease in interleukin (IL)-2, interferon (IFN)- and tumour necrosis factor (TNF)- 
production and an increase in the production of transforming growth factor (TGF)-51-
53. It has been demonstrated that T cell responses to Id in SLE depend on somatic 
hypermutation in the V region of antibodies as non-mutated V regions failed to activate 
T cells and non-mutated antibodies were not immunogenic in immunization 
experiments54,55. 
 
1.2.3 Presentation of Id to Id-specific T cells 
As mentioned above, Ids may be presented to Id-specific T cells by APCs such as DCs. 
The immunogenicity of Id is particularly interesting considering the fact that B cells 
constitutively present endogenous Ig-derived peptides in combination with MHC 
molecules on the cell surface56-58. In B myeloma cells, this was shown to be independent 
of Ig secretion or expression of membrane bound Ig, suggesting processing of  newly 
synthesized Igs in the endoplasmatic reticulum (ER)59. Presentation of Id may in the 
majority of cases induce tolerance in responding T cells33,60,61. However, B cells also 
present rare Id-peptides, which can be recognized by CD4+ T cells on MHC class II 
molecules61,62 and by CD8+ T cells on MHC class I molecules63,64. This may lead to 
activation of the responding Id-specific T cells59,65. Moreover, the reciprocal Id-driven 
collaboration between T and B cells may sustain the activation, the proliferation and the 
differentiation of Id-bearing B cells66,67. These studies have shown that B cells have the 
ability to directly stimulate T cells in the absence of conventional antigen, contradicting 
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the generally accepted belief that the collaborating T cell and B cell must recognize 
epitopes on the same molecular complex. This concept has been termed non-linked 
recognition66. Thus, there are two ways by which an Id-specific T cell may receive 
cognate activation: i) An APC may phagocytose and process soluble Id-bearing Ig and 
present Id-peptides to an Id-specific T cell, and ii) an Id-bearing B cell may present 
endogenous Ids from its own receptor to Id-specific T cells (Figure 1).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FcR
TCR MHC
Id-specific 
CD4+ T cell
Id-specific 
CD4+ T cell
APC
Id-peptide
Id-bearing Ig
B)
A)
B cell 
ER
 
 
Figure 1. Presentation of Id to Id-specific T cells.  
A) Soluble Id-bearing Ig may be taken up by an APC, which processes and presents Id-
peptides to an Id-specific T cell. B) An Id-bearing B cell may process and present Id-
peptides from endogenous Ig molecules in combination with MHC class II to an Id-
specific CD4+ T cell. 
 
Transgenic mice expressing 2 positive B cells (Id+) or the corresponding TCR have 
facilitated the study of Id-driven T-B cell collaboration in vivo66. Id-specific T cells 
injected into Id+ mice were shown to stimulate B cell activation and generation of 
germinal centers, plasma cells and production of autoantibodies66. By repetitive 
injection of Th2 cells it was shown that Id+ mice developed lymphomas after a latency 
period of more than 5 months68. This demonstrated that Id-specific T cells not only 
could eliminate Id+ B cells, but also provide help and sustain tumour growth. The 
generation of Id-matched double transgenic mice allowed the study of Id-driven T-B 
cell collaboration from early ontogeny69. These mice were shown to develop systemic 
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autoimmunity with manifestations in skin, bowel and joints in addition to inflamed 
tissue containing foci of cells resulting from Id-driven T-B cell collaboration. 
Furthermore, T cells and B cells from the spleen of double transgenic mice were shown 
to transfer disease to mice deprived of immune cells.  
 
1.2.4 Id responses in human disease  
The contribution of Id-specific responses in the development of human disease is less 
clear. Id-specific T cells have been reported in SLE, rheumatoid arthritis and MS. A 
human anti-single stranded DNA antibody carrying the Id 16/6 Id can induce SLE in 
mice70. This Id was found to be present in anti-DNA autoantibodies of 50-60 % of 
patients with active SLE compared to 4 % in healthy controls44,45,70-72. When assessing 
proliferative responses in blood T cells to the same Id or peptides corresponding to the 
CDRs of the 16/6 Id, a significantly weaker response was detected in patients compared 
to healthy controls45,70,72. The proliferative capacity of Id-specific T cells declined along 
with exacerbations of the disease. Accordingly, CDR peptides specifically inhibited 
16/6 induced proliferation and IL-2 production. The latter correlated with increased 
expression of the regulatory cytokine TGF-, suggesting the involvement of regulatory 
T cells in the anti-Id response in SLE patients73. 
 
Joint-derived polyclonal T cells from rheumatoid arthritis patients have been found to 
proliferate in response to autologous IgG H chains74,75. The response was shown to be 
human leukocyte antigen (HLA) restricted, but since T cells also proliferated in 
response to plasma IgG, the specificity of the response was uncertain.  
 
As will be discussed thoroughly in this thesis, Id-specific responses including Id-driven 
T-B cell collaboration may contribute to the chronic inflammation in MS.  
 
1.3 Autoimmunity; protective and pathogenic aspects  
Autoimmunity can be defined as an adaptive immune response directed against the 
body’s own tissues. At the beginning of the twentieth century, the German physician 
Paul Ehrlich coined the term “horror autotoxicus” arguing that the normal body would 
never mount an immune response against its own tissue. According to this view, any 
autoimmune reaction was destructive and connected to human disease. We now know 
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that the causal relationship between autoimmune reactions and autoimmune diseases is 
more complex.  
 
It is estimated that about 20-50 % of the TCRs and BCRs created during VDJ 
recombination are self-reactive76,77. Although most T and B cells carrying such self-
reactive receptors are deleted during maturation78,79, a high frequency of autoreactive T 
cells, B cells and autoantibodies is present in the normal repertoire without causing 
disease77,80. Indeed, it is proposed that recognition of self is essential for survival of 
naïve lymphocytes and that it can enhance reactivity to foreign antigen81, that it may 
regulate the extent and duration of immune responses24, and that autoantibodies can 
contribute to the clearance of damaged tissue82. Furthermore, recognition of self-
proteins in the absence of costimulation is important for the maintenance of 
immunological tolerance83-85. 
 
1.3.1 Protective autoimmunity in the central nervous system 
Studies in rodents have shown that the same myelin basic protein (MBP) specific T cells 
that cause EAE in mice also can have a protective function by reducing secondary 
degeneration of neurons after primary injury to the optic nerve or spinal cord86,87. The 
effect was shown to be specific for T cells reactive with central nervous system (CNS) 
antigens, as T cells with other specificities did not confer protection even though they 
were shown to home to the injury site86. A follow-up study demonstrated that 
suppression of the autoimmune reaction by tolerance induction to MBP or by the 
injection of CD4+CD25+ regulatory T cells reduced the protective effect of MBP 
specific T cells88. Thus, a degree of autoimmunity was required to confer protection. 
These observations have implicated T cells as important mediators of CNS 
neurogenesis, the process by which neuronal precursor cells give rise to new neurons in 
certain areas of the brain89,90. Accordingly, it was shown that T cell deficient mice 
displayed decreased neurogenesis from endogenous precursor cells compared to normal 
mice, and that this could be partly restored by reconstitution of the T cell pool91. 
 
The protective effect of CNS reactive T cells most likely involves activation of local 
APCs present at the injury site92,93. It was demonstrated that activation of microglia by 
either the Th1 cytokine IFN- or the Th2 cytokine IL-4 induced neuronal and 
oligodendroglial differentiation from adult neuronal precursor cells94. It was accordingly 
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hypothesized that the release of cytokines may serve a function in the recruitment of 
neuronal precursor cells to the injury site. In support of this, neuronal precursor cells 
layered onto hippocampal slice cultures were shown to migrate towards sites treated 
with inflammatory stimuli, such as TNF- or IFN-95. This was dependent upon 
cytokine-induced upregulation of chemo-attractants. Differentiation of progenitor cells 
arriving at the injury site may in part be mediated by growth factors. Activated 
microglia and macrophages have been shown to secrete a variety of growth factors in 
vivo96, and may reciprocally induce the production of growth factors in other cells91. 
Furthermore, activated human T cells, B cells and monocytes in inflammatory MS 
lesions as well as myelin oligodendrocyte glycoprotein (MOG) reactive T cells from 
healthy individuals express nerve growth factors97,98.  
 
1.3.2 Autoimmune diseases  
The relation between benign autoimmunity and the progression and establishment of an 
autoimmune disease is unclear. An autoimmune disease can be organ specific, such as 
in type 1 diabetes and MS or systemic such as in SLE and Sjogren’s syndrome and is 
characterized by a chronic adaptive immune response directed against self-tissue. About 
3-5 % of the world’s population is affected by an autoimmune disease99 with women 
accounting for 78 % of cases100. It is believed that a combination of risk-associated 
polymorphisms in immunoregulatory genes, infectious agents and other environmental 
triggers contribute to the initiation and propagation of disease101,102. Thus, a few 
examples of human autoimmune diseases induced by defined microbes exist, such as 
rheumatic fever103 and Guillain-Barré syndrome104. These are thought to arise from 
antigenic mimicry between the infectious agent and human tissue triggered during the 
initial inflammatory response. For the majority of human autoimmune diseases, 
however, the link to infection remains circumstantial. This may be due to the time lag 
between infection and establishment of disease and the potential contribution of 
subclinical infections.  
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1.4 Immune surveillance of the central nervous system 
The CNS is comprised of the brain and spinal cord, surrounded by three layers of 
meningeal membranes105. The blood brain barrier (BBB) is a feature of the cerebral 
vasculature, which restricts access of ions and other solutes present in the blood into the 
brain parenchyma. The anatomical structure of the BBB comprises two cell layers, 
which are separated by the perivascular space. One is formed by endothelial cells lining 
the brain capillaries and an underlying basement membrane, and the other is formed by 
astrocytic foot processes and their parenchymal basement membrane. Unlike in other 
tissues, the endothelial cells of the BBB display no fenestration and are connected by 
tight junctions, which efficiently restrict the traffic of molecules and cells in and out of 
the brain. The cerebrospinal fluid (CSF) baths the brain and is produced from arterial 
blood by the choroid plexus106. It flows from the ventricles of the brain into the 
subarachnoid space located between the arachnoid and the pial membrane and is 
eventually absorbed into the venous circulation107. The CSF communicates with the 
interstitial fluid of the brain through the perivascular spaces. Due to the lack of tight 
junctions in the ependymal linings of the ventricles, small hydrophilic molecules as well 
as proteins diffuse freely between the CSF and brain interstitium108. 
 
Under physiological conditions, immune cells enter the CNS at a very low level for the 
purpose of immune surveillance109-111. In contrast, during inflammatory diseases such as 
MS, activated cells readily traverse the inflamed BBB110. CNS fluids continuously drain 
into cervical lymph nodes, ensuring communication with the peripheral lymphoid 
system112, but the absence of secondary lymphatic structure, the low expression of MHC 
class II molecules and the lack of DCs in the CNS have questioned how immune 
surveillance of the brain takes place under physiologic conditions113,114. 
 
Perivascular cells within the subarachnoid space probably play a key role in immune 
surveillance. It is suggested that activated memory cells enter the CSF from the 
systemic circulation and monitor the subarachnoid space under physiologic 
conditions105,111. This is strongly supported by observations in EAE where parenchymal 
inflammation and disease onset is preceded by inflammation and accumulation of Th17 
polarized CD4+ T cells in the subarachnoid space115-117. Furthermore, it was recently 
demonstrated that Th17 cells expressing the chemokine receptor CCR6 were allowed 
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access into the perivascular space through the choroid plexus by interaction with the 
CCR6 ligand, CCL20118. This step triggered and was indispensable for a second wave 
of inflammation mediated by T cell infiltration through the BBB. CCR6 was found to be 
constitutively expressed by cells of the choroid plexus also in humans, and the entry of 
Th17 cells into the CSF was suggested to control immune surveillance of the CNS 
during physiologic condition.  
 
1.4.1 Migration of cells across the blood brain barrier  
The migration of mononuclear cells across an inflamed BBB is a two-step process, 
which first requires entry across the endothelial cell layer and its basement membrane 
into the perivascular space. Several adhesion molecules, including activated leukocyte 
cell adhesion molecule, ICAM, VCAM-1, 4-integrin and laminins seem to be 
selectively involved in the adhesion and transmigration of T cells119-123. Adhesion 
molecules are believed to aggregate in microdomains on the endothelium, so-called 
transmigratory cups, which guide the migration of lymphocytes across inflamed 
cerebral vessels. The monoclonal antibody (mAb) natalizumab, used in the treatment of 
MS, efficiently inhibits the infiltration of lymphocytes into the brain by blocking the 
VCAM-1-ligand, 41-integrin124. Furthermore, T cell transmigration could be 
selectively inhibited by laminin-5, an adhesion molecule expressed on the endothelial 
basement membrane125.  
 
To reach the brain parenchyma from the perivascular space leukocytes must traverse the 
parenchymal basement membrane and the glia limitans, a thick layer of astrocytic 
processes that seals the entire surface of the CNS. The molecular mechanisms 
facilitating this step are less defined, but thought to rely on the secretion of matrix 
metalloproteinases (MMPs) by perivascular macrophages or DCs. Hence, mice were 
made resistant to EAE by deletion of MMP-2 and MMP-9, and T cells were trapped in 
the perivascular space126. Thus, cells that gain access to the perivascular space through 
interaction with inflamed brain endothelium may only traverse the glia limitans into the 
parenchyma if they recognize their cognate antigen presented by perivascular 
APCs127,128. Also the strength of lymphocyte reactivation in the perivascular space may 
determine migration into the brain parenchyma129. MHC expression by endothelial cells 
may also play a role in the recruitment of antigen specific T cells as was recently 
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demonstrated for the migration of CD8+ T cells across the BBB130. Finally, T cells that 
infiltrate the brain parenchyma may interact with resident microglia, which in response 
to CNS inflammation acquire a macrophage-like phenotype with increased expression 
of costimulatory and adhesion molecules131.  
 
1.5 Multiple Sclerosis 
MS was first described in 1868 by Jean-Martin Charcot132, but early reports of people 
suffering distinct neurological symptoms analogous to MS date back to the middle 
ages133,134. Today MS has a prevalence that generally ranges from 2-150 per 100,000, 
although this can be significantly higher in certain regions135. The etiology of MS is 
complex and involves genetic and environmental factors136-138. 
 
1.5.1 Clinic 
MS usually presents with a clinically isolated syndrome, a neurological episode 
suggestive of inflammation and demyelination, but not sufficient by itself to qualify for 
an MS diagnosis139. In the majority of patients, disease typically evolves with irregular 
relapses followed by more or less complete remission. The use of magnetic resonance 
imaging allows visualization of affected CNS sites. Radiological evidence of 
demyelination episodes disseminated in time and space is part of the revised diagnostic 
criteria for MS140. At the onset of disease, the majority of patients follow a relapsing-
remitting (RR) course, whereas in about 15 % of patients, disease progresses without 
intermittent relapses in what is referred to as primary progressive MS141. Progression of 
disease in most RRMS patients will over time also be devoid of remissions and evolve 
into a secondary progressive course142. 
 
1.5.2 Etiology 
Clustering of MS cases within families and the sharp decline in concordance with 
increasing genetic distance demonstrate the genetic contribution to MS136. The strongest 
genetic association to MS is found within the HLA complex. The HLA-DRB1*1501 
allele is thought to confer the primary association in Caucasians and Afro-
Americans143,144. Lately, genome wide association studies have pointed out an 
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association between MS and immunoregulatory genes encoding IL-2 and IL-7 receptor 
 chains, which are associated with activation and homeostasis of T cells145,146.  
 
Several observations demonstrate the environmental contribution to MS risk: i) the 
relative low concordance rate in monozygotic twins, ii) the influence on MS risk by 
migration to areas of low or high MS prevalence, and iii) the increase in female: male 
sex ratio observed over time137,138. Both infectious and non-infectious factors, such as 
vitamin D and smoking, have been implicated by epidemiological evidence. It seems 
that environmental factors in childhood contribute to MS risk and a study on adoptees 
have demonstrated that environmental factors in MS operate on a population basis and 
not in the microenvironment147.  
 
Of many possible infectious agents suggested to confer MS risk, Epstein-Barr virus 
(EBV) is supported by the strongest epidemiological evidence. MS risk is higher in 
individuals with a past history of infectious mononucleosis, and a temporal increase in 
serum titres of antibodies to EBV has been shown to correlate with the onset of MS later 
in life148. The functional relevance of EBV in MS is supported by a higher frequency of 
EBV specific T cell in MS patients149 and by the demonstration of MBP specific T cells 
that cross react with EBV-proteins150,151. Furthermore, strong CD8+ T cell responses to 
EBV can be detected in cases of early MS152. After the identification of EBV-infected B 
cells in white matter lesion in MS153, the importance of EBV and EBV specific T cells 
in MS have gained new ground. However, this observation, which may prove seminal in 
terms of understanding MS pathogenesis, awaits confirmation, and the specificity of 
CD8+ T cells found in the vicinity of EBV-infected B cells has not been identified. 
 
1.5.3 Pathogenesis  
Lesson from EAE have guided much of the research in MS and formed the long-held 
view that myelin specific CD4+ cells play a key role in MS. EAE is caused by a direct 
attack on myelin proteins mediated by myelin specific CD4+ T cells154. EAE can be 
induced in susceptible strains of rodents and nonhuman primates through immunization 
with myelin proteins or peptides emulsified in complete Freund’s adjuvant. 
Alternatively, adoptive transfer of activated myelin specific T cells can induce EAE. 
Although the EAE model may reflect important pathogenic mechanisms in MS, 
observations such as a dominance of clonally expanded CD8+ T cells in active MS 
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lesions, perpetual intrathecal production of oligoclonal IgG fractions in MS patients, 
and the failure to firmly establish myelin proteins as target antigens in MS underscore 
critical differences in the pathogenesis of human MS and animal EAE155. 
 
The clinical benefit of blocking migration of lymphocytes into the CNS or of strong 
immunosuppression with mAbs has for the first time provided conclusive evidence for 
the detrimental effect of the immune response in MS156,157. However, whether the 
immune response in MS is primarily autoimmune or secondary to neurodegeneration 
elicited by other factors is still not settled. According to the autoimmune hypothesis of 
MS, it is assumed that effector CD4+ and CD8+ T cells are primed in secondary 
lymphoid organs through antigen specific T cell-APC interactions158. In view of recent 
findings, it may be proposed that reactivation of antigen specific Th17 cells in the 
perivascular space plays a crucial role for the transmigration of other T cell 
subsets117,118. The upregulation of adhesion molecules and corresponding ligands by 
brain epithelium and activated lymphocytes allows the migration of activated T cells 
and B cells across the BBB. It is believed that only those T cells that recognize cognate 
antigen will be retained in the brain110. Reactivation may occur by cross recognition of 
myelin or neuronal antigens, by recognition of an original infectious agent153 or of other 
antigens present in the brain, such as Ids159. Reactivation of T cells triggers 
parenchymal inflammation, which recruits T cells, B cells, DCs and microglia to the site 
of inflammation. The release of pro-inflammatory cytokines, direct damage mediated by 
MHC class I restricted CD8+ T cells and indirect damage by MHC class II restricted 
CD4+ T cells, complement deposition and local activation of microglia and 
macrophages160 may all have a role in the inflammatory response. The reason why the 
immune response becomes chronic remains unknown, but could be explained by site-
specific expression of autoantigens, persistence of latent infections, a permissive CNS 
environment or a combination of all.  
 
1.5.4 The intrathecal immune response in MS 
A hallmark of the immune response in MS is the formation of isolated areas of 
inflammation called lesions or plaques. Lesions can appear throughout the brain, both in 
the white and in the grey matter and are often found around the ventricles, in the optic 
nerve, in the brain stem and in the spinal cord161. Within lesions the most characteristic 
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pathological feature is demyelination. Axonal damage is probably present from early in 
the disease process and numerous transected axons can be visualized in active 
lesions162. Mononuclear infiltrates of CD4+ T and CD8+ T cells, B cells and 
macrophages are present to various extents and are thought to be critical for disease 
development and progression. Much effort has been devoted to analyzing the phenotype 
of T and B lymphocytes dominating in the intrathecal compartment as a means to 
identify potential antigens and to understand the underlying disease process.  
 
1.5.4.1 T cells 
Within the active lesion clonally expanded CD8+ T cells outnumber CD4+ T cells, 
which are more polyclonal and often found in the periphery of the lesion163,164. By 
analyzing 22 tissue blocks from patients and healthy controls, the majority of T cells in 
active MS lesions were found to express IL-17165. Unlike what is described for EAE, 
both CD4+ and CD8+ T cells from MS lesions stained positive for IL-17. Their 
expression of cytolytic granules and their ability to kill neurons in vitro166 have pointed 
out Th17 cells as a critical subset of T cell in MS167. 
 
T cells within MS lesions display a restricted receptor repertoire168,169, suggesting that a 
limited number of clones participate in local immune reactions. Furthermore, central 
memory T cells within MS lesions have been shown to lack CCR7170, indicating that 
they had differentiated into effector T cells upon restimulation with antigen. However, 
the antigen-specificity of T cells in MS remains unclear. In light of EAE, the search for 
an MS target antigen has revolved around myelin peptides, but the role of myelin 
specific T cells in MS is uncertain. The frequency of MBP specific T cells is 
overlapping in MS patients and controls, although T cells from MS patients seem to 
display a higher frequency of activation markers and tend to belong to the memory pool 
of T cells171. A phase II clinical trial where MS patients were immunized with an altered 
peptide ligand based on an immunodominant MBP epitope, resulted in clinical 
exacerbations associated with an increase in the frequency of T cells specific for the 
MBP epitope172. This suggests that MBP specific T cells may cause encephalomyelitis 
also in humans, but does not pinpoint MBP specific T cells as culprits in MS. In a 
young patient suffering from hyperacute MS, T cell infiltrates were shown to display 
reactivity to myelin proteins173. However, earlier attempts to chart the specificity of T 
cell clones isolated from MS lesions have not detected reactivity to MBP or proteolipid 
 25
protein (PLP)174. The pathogenic role of myelin specific T cells is further complicated 
by the therapeutic potential these cells may have175. 
 
The search for alternative antigens in MS has suggested the stress protein B-crystallin 
as a potential target. B-crystallin is a small heat shock protein and one of the most 
abundantly expressed proteins that is found in active MS lesions, but not in normal 
brain176,177. In comparison to a variety of other myelin proteins, which included MBP, 
PLP and MOG, B-crystallin elicited strong proliferative responses in peripheral blood 
lymphocytes from MS patients. Thus, other potential T cell targets in MS may be 
proteins expressed uniquely in MS brains and not in normal brain178.  
 
1.5.4.2 B cells 
Several observations demonstrate that B cells are involved in the disease process of MS. 
B cells as well as deposits of Ig and complement are found within MS lesions179 and 
more than 95 % of MS patients display a perpetual intrathecal synthesis of oligoclonal 
Ig, which can be visualized as distinct oligoclonal bands (OCBs) by isoelectric focusing 
or agarose gel electrophoresis. The OCBs of MS patients are predominantly IgG1. 
OCBs can also be observed in infectious diseases of the CNS where the antigenic target 
is the infectious etiologic agent180,181.  
 
Analyses of transcribed BCR V genes from CSF and MS lesions have revealed a 
population of B cells that is clonally expanded, displays a limited H chain repertoire and 
that contains numerous replacement mutations182-187. These observations strongly 
suggest that B cells in MS are the result of an antigen-driven T cell dependent process. 
Prominent clonal expansion of CSF B cells is an early feature of MS, suggesting that 
antigen-specific B cell responses may be implicated at the onset of disease188,189. Short-
lived plasma blasts are probably the major antibody-secreting cell in the CSF and 
described as the main effector population190,191. A comparison of the Ig transcriptome of 
B cells with the corresponding Ig proteome in the CSF of four MS patients established 
that CSF B cells were at least one possible source of the OCBs186. However, OCB 
formation in CSF may result from B cell activation within the CNS parenchyma and 
whether B cells present in the CSF correlate with CNS B cells is not clear. Efforts to 
identify the specificity of the main oligoclonal IgG in MS remains a challenge192.  
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Antibodies with reactivity against myelin proteins can readily be detected in the CSF of 
MS patients193,194. IgG from CNS tissue was found to contain anti-MOG antibodies in 
seven of 14 MS patients195, and although debated, serum antibodies specific for MBP 
and MOG have been suggested as an early diagnostic marker for MS196,197. Also, it was 
recently demonstrated that nine out of 10 antigen binding fragments from clonally 
expanded CSF B cells from four MS patients recognized MBP198. However, the 
pathogenic relevance of myelin specific antibodies in MS remains uncertain.  
 
A curious feature of MS is the perpetual intrathecal production of virus specific 
antibodies199,200. These antibodies are typically directed towards measles, varicella 
zoster, rota and mumps viruses199,201,202. They mainly display IgG1 subclass 
restriction203 and are also present in vaccinated individuals204. Virus specific antibodies 
display an oligoclonal pattern, but are not part of the main OCBs and constitute only a 
small fraction of intrathecally synthesized IgG181,199. Moreover, clonally expanded CSF 
B cells cultured in vitro were shown to display specificity for the same viruses as that 
described for intrathecally produced antibodies205. The fact that some of these 
antibodies are directed against RNA-viruses that most probably do not persist in the 
CNS, suggests that they are not a result of an ongoing virus specific immune response. 
 
Whether the intrathecal humoral immune response in MS is pathogenic or represents an 
epiphenomenon has been unclear. However, there are several indications that B cells in 
MS may play a role in the disease process beyond their capacity to produce antibodies. 
Ectopic lymphoid follicles enriched with B cells and plasma cells have been observed in 
the meninges of patients with secondary progressive MS206, compatible with an ongoing 
B cell differentiation at least in late stages of the disease. The formation of local 
germinal center-like structures has also been described in other autoimmune 
conditions207 and may be a common feature of chronic inflammatory responses. In the 
case of MS, this may suggest that maturation of B cells takes place in the intrathecal 
compartment. This view is supported by the presence of centroblasts, a B cell 
population typical of secondary lymphoid organs, in the CSF208. In addition, antigen 
dependent short-lived plasma blasts are common in the CSF191. These observations are 
intriguing in light of the therapeutic potential of rituximab209. Rituximab targets CD20, 
which is carried by B cells at all stages of B cell differentiation, except for pro-B cells 
and plasma cells. A near complete deletion of CD20 expressing B cells in the CSF and 
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blood was observed in treated patients, who concomitantly experienced a marked 
reduction in clinical attacks and a decrease in the number of lesions. Moreover, 
following 24 weeks of rituximab treatment the number of CD3+ T cells in the CSF was 
significantly reduced in the majority of patients210. However, the IgG concentration in 
CSF, the IgG index, the IgG synthesis rate and the number of OCBs were not 
affected210. This may suggest that the therapeutic effect of rituximab is independent of 
antibody production and that other B cell effector functions are involved, such as 
bystander activation through cytokine secretion or the ability to present antigen to T 
cells171. 
 
1.6 Glatiramer acetate in the treatment of MS 
Currently seven drugs are officially approved for the treatment of MS, while many new 
therapies are emerging. For the most part these include agents that either interfere with 
lymphocyte migration, activation or proliferation, or that modulate 
neurotransmission211. Included are also antigen-specific therapies, which may be 
promising candidates considering the often-observed limited effect and potential serious 
adverse effects of currently approved and upcoming drugs. Glatiramer acetate (GA) is 
one of the first-line drugs for the treatment of RRMS and its immunomodulatory 
potential has been a topic in this thesis.  
 
GA is a synthetic copolymer comprised of the four amino acids most frequent in MBP; 
glutamine, alanine, lysine and tyrosine. The idea was that GA would be sufficiently 
identical to MBP in terms of sequence and antigenicity that it could be used as a 
substitute for the induction of EAE. Administration of GA unexpectedly showed the 
opposite effect; mice were protected against the development of clinical disease212. A 
phase III, multicenter, double blind, placebo-controlled trial, which included 251 RRMS 
patients, demonstrated a 29 % reduction in relapse rate compared to placebo in patients 
who received GA for two years213,214. This result was the main basis for the subsequent 
approval by the US federal drug administration of GA for the treatment of MS. 
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1.6.1 Effects on the immune system  
GA binds with high affinity to HLA class II molecules of the DR isotype, and can do so 
without prior processing215,216. GA seems to have a number of effects on APC function, 
such as a reduction in the secretion of pro-inflammatory cytokines and an increase in the 
secretion of anti-inflammatory cytokines217-219. This may in turn induce an anti-
inflammatory phenotype in GA reactive T cells220,221. A GA-induced shift in the 
cytokine profile of GA reactive T cells towards an anti-inflammatory phenotype has 
been demonstrated in patients by comparing the cytokine profile of GA reactive blood T 
cell lines before and after treatment222,223. Additionally, GA may lead to anergy-
induction of pathogenic lymphocytes224,225, and restoration of function and frequency of 
regulatory T cells226-228. 
 
1.6.2 Cross reactivity  
Due to similarities in amino acid composition to MBP recognition of MBP has been 
thought to account for the reactivation of GA reactive T cells in the CNS229. This has 
been based upon the observations that GA reactive T cells accumulated in the CNS of 
GA-treated mice230,231 in combination with studies demonstrating cross reactivity 
between MBP and GA as assessed by cytokine secretion229,231,232. In mice, GA reactive 
T cells were shown to react to MBP by secretion of IL-4, IL-6 and IL-10229 and to target 
the immunodominant epitope 82-100 of MBP by TCR antagonism233. The secretion of 
anti-inflammatory cytokines is thought to mediate bystander suppression of nearby 
pathogenic T cells within the CNS231. However, GA is not only efficient in MBP-
induced EAE, but also in PLP and MOG-induced disease234,235, suggesting either that 
cross reactivity with MBP is not essential for the therapeutic effect or that cross 
reactivity is a more general phenomenon.  
 
Studies using human T cell lines have either failed to detect cross reactivity between 
GA and myelin proteins236,237 or reported it as a low frequency or unspecific 
event222,223,238,239. GA reactive T cell lines from six of seven patients displayed cross 
reactivity to random combinatorial peptide libraries, including peptides from MBP. 
Cross reactivity was determined by cytokine secretion and was consistent with a 
degenerative response as no dominantly cross reactive peptide emerged222. Two other 
studies reported cross reactivity to MBP by cytokine secretion in 10-25 % of GA 
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reactive cell lines223,239. Cross recognition assessed by proliferation was observed for 
three of 18 GA reactive cell lines against MBP in a patient treated with GA for 6 
years238. Together these observations suggest that cross reactivity may occur, but that 
other mechanisms probably contribute to the efficacy of GA reactive T cell inside the 
CNS. 
  
1.6.3 Neurotrophic effect  
The therapeutic effect of GA is postulated to involve neuroprotection240. GA reactive T 
cell lines from MS patients and healthy controls have been shown to display low basal 
secretion of brain-derived neurotrophic factor (BDNF), which increased upon 
stimulation with GA241,242. In mice, in situ secretion of BDNF by GA reactive T cells 
correlated with reduced neuronal damage as well as increased neuronal proliferation243, 
and GA treatment was recently shown to induce remyelination in EAE244. Secretion of 
BDNF is not restricted to GA reactive T cells, but seems to be a more general feature of 
activated cells. T cells, B cells and monocytes have all been demonstrated to secrete 
BDNF in vitro and in inflammatory brain lesions97. This may suggest that the daily 
injection of GA promotes BDNF secretion as a result of a continuous activation of GA 
reactive peripheral T cells, which subsequently gain access to the CNS245. 
 
Taken together, studies in mice suggest that GA has the ability to support growth of 
nervous tissue240,243,244. To which extent this applies also in humans is less clear and 
needs further attention using human cells and tissue. However, the observed long-term 
clinical efficacy of GA may support both an anti-inflammatory and a neurotrophic effect 
of GA246. 
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2. AIMS OF THE STUDY 
Although the intrathecal immune response in MS is predominantly detrimental to the 
CNS, there seems to be protective elements as well. In contrast to animal studies where 
the effect of T cell responses against specific antigens can be studied directly, the 
pathogenic significance of any particular T cell response in humans is usually unknown. 
Thus, T cell responses to Ids could be either irrelevant or pathogenic, or they could be 
part of a regulatory and anti-inflammatory network. GA provides an exceptional 
opportunity to study a T cell response with a proven beneficial clinical effect. The 
overall aim of this thesis has been to explore the detrimental and beneficial effects of 
intrathecal T cell responses, by using GA and Id as model antigens. The specific aims of 
the thesis were:  
 
 To establish whether GA reactive T cells gain access to the intrathecal 
compartment of MS patients, and if so, then characterize their cytokine profile 
 
 To characterize the T cell epitopes on autologous CSF IgG molecules 
 
 To identify the target antigens of CSF B cells potentially involved in Id-driven 
T-B cell collaboration 
 
 To develop an in vitro model to study the pathogenic potential of Id-specific T 
cells 
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3. METHODOLOGICAL CONSIDERATIONS  
 
3.1 The generation of T cell lines and clones 
T cell lines and clones employed in this thesis have been generated from the CSF and 
blood of MS patients. Patients involved in this thesis are described in Table 1.  
 
Patient Age at study onset Diagnosis at study onset Paper 
MS 1 38 SPMS II, III and IV 
MS 2 39 RRMS II and III 
Patient 1 20 RRMS I 
Patient 2 32 RRMS I 
Patient 3 29 RRMS I 
Patient 4 32 RRMS I and IV 
Patient 5 38 RRMS I 
   
Table 1. Patients involved in the study. SP = secondary progressive 
 
For the generation of CSF T cells approximately 20-25 ml of CSF was obtained from 
patients by lumbar puncture. The first two ml of CSF was always discarded because 
even minute amounts of blood would render the CSF sample unrepresentative. Due to 
the low number of cells present in the CSF, T cells were expanded to allow subsequent 
study. T cells from blood and CSF were cultured in parallel following identical 
procedures to minimize the differences in the cell populations as a result of in vitro 
manipulations.  
 
For the first two weeks of culture T cells were expanded in the presence of autologous 
peripheral blood mononuclear cells (PBMCs), which had been preincubated with 
antigen overnight. Previous experiments have shown that the presence of antigen in the 
absence of mitogens in the culture medium is important for the initial propagation of 
antigen specific T cells from the CSF151. To avoid propagation of allospecific T cells, 
auotologus serum was used for the first two weeks of culture. Since activated T cells 
express high affinity IL-2 receptors, T cells were further expanded with the addition of 
IL-2. This favours expansion of T cells with strong proliferative capacities that have 
been triggered by antigen in vitro. Further expansion of antigen-specific T cells was 
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done in the presence of the T cell mitogen phytohemagglutinin (PHA), IL-2 and 
heterologous feeder cells. Antigen responsive T cell lines were cloned by limiting 
dilution by seeding 0.1-1 cell per well. The cloning frequency was 3-27 %, which 
makes it more than 95 % likely that each cell culture is monoclonal247. As IL-15 has 
been shown to upregulate anti-apoptotic proteins in activated T cells248 it was included 
in the culture to increase survival of resting cells.  
 
An important consideration when comparing T cells from CSF and blood is that in vitro 
expansion may differently affect the two cell populations due to heterogeneity in their 
putative receptors and activation status. Antigen priming in combination with cytokine 
stimulation may expand both naïve and memory T cells. This is most relevant when 
expanding cells from blood as a great proportion of these are of a naïve phenotype. In 
contrast, the majority of T cells present in CSF are of an activated memory 
phenotype249-251. However, it may be argued that the in vitro conditions employed 
preferentially expand T cells of a memory phenotype from both compartments as these 
will respond faster to antigen stimulation and therefore dominate the cell culture. 
  
 Also, in vitro expansion may preferentially expand different phenotypes or affect the 
cytokine profile of expanding cells. We were, however, able to expand both Th1 and 
Th2 polarized GA reactive T cell lines from both blood and CSF (Paper I), indicating 
that the in vitro procedure is well suited for expansion of several phenotypes of CD4+ T 
cells.  
 
Because CD4+ T cells have been the focus in this study, in vitro cell culture conditions 
that preferentially expand this subset have been employed throughout the study. 
Considering the high number of clonally expanded CD8+ T cells both in CSF and CNS 
of MS patients163,252, this would clearly be an interesting subset to expand and 
investigate. However, studies on CD8+ T cell in CSF mostly rely on direct analysis and 
the expansion of antigen-specific CD8+ T cells from the CSF is challenging and not well 
described. 
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3.1.1 Characterization of T cell epitopes on CSF mAbs 
The CSF mAbs were generated from EBV-transformed B cell clones isolated from the 
CSF of patient MS1 and MS2. The purification procedure and testing for potential 
contaminants are outlined in paper II, but will not be discussed here, as this was not part 
of the work performed in this thesis.  
 
The nucleotide sequences of the VL and VH regions of the two CSF mAbs were 
obtained from polymerase chain reaction (PCR) amplified complimentary DNA of the 
EBV-transformed B cells. By comparing the CSF mAb sequences to the closest 
germline encoded sequences, the frequency and distribution of amino acid replacements 
were identified. To chart T cell epitopes of CSF mAb specific T cell clones, a panel of 
peptides (>70 % pure) covering mutated sequences and the highly variable CDR3s of 
the VL and VH chains of the CSF mAbs was synthesized. Lyophilized peptides were 
stored at -70° C and dissolved in dimethyl sulfoxide (DMSO) before they were added to 
the culture medium. The final concentration of DMSO in the cell culture medium was 
always far below toxic concentrations.  
 
3.1.2 Testing of cross reactivity of GA specific T cell clones. 
The ability of GA reactive T cells to cross react with myelin proteins is thought to 
account for the reactivation of GA reactive T cell in the CNS230. We tested 20 GA 
specific T cells clones against recombinant human MBP and a panel of 531 15-mer 
overlapping peptides spanning the complete amino acid sequences of MBP, PLP, MOG, 
myelin-associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMGP), 
-cystallin, s100 and 2’-3’cyclic nucleotide 3’-phosphodiesterase (CNPase). Potential 
cross reactivity was assessed by proliferation and by cytokine secretion. The peptides 
were synthesized at a purity of 44-100 %. Although only 0.5 % of the peptides had a 
purity of less than 50 %, it may be criticized that the peptide fractions could contain 
contaminants. However, as no cross reactivity was detected the problem of false 
positives was not relevant. T cell clones were tested against pools of 8-10 peptides at a 
concentration of 2.5 M. Higher concentrations were not used due to the potential toxic 
effect of the dissolvent, DMSO. Bearing in mind the low dose of GA needed to 
stimulate GA specific T cell clones (responded to 160 ng/ml of GA), and the 
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significantly lower concentration of individual stimulating peptides in the GA mixture, 
2.5 M was considered a sufficient dose to identify cross reactivity. A shortcoming of 
this assay is that myelin specific T cell clones were not included as positive controls. 
The same peptide panel was, however, used in a previous study and shown to elicit 
proliferative responses of CD4+ T cells from MS patients253. 
 
3.2 Testing of T cell responses 
 
3.2.1 T cell proliferation assays 
 
T cell proliferation was assessed by [3H] thymidine incorporation, which was chosen for 
its robustness and ease by which large numbers of wells can be assayed simultaneously. 
T cells were stimulated to proliferate by receptor engagement, either by specific 
recognition of antigen in the presence of APCs or by addition of monoclonal anti-CD3 
and anti-CD28 antibodies. This assay was ideal for screening and monitoring the large 
number of cell lines and clones established from each patient. A weakness of assaying 
initial cell cultures with proliferation alone is that cells with a non-proliferative 
phenotype may have been missed. 
 
3.2.2 Detection of cytokine production  
In addition to [3H] thymidine incorporation several of the T cell lines and clones were 
analyzed for the secretion of cytokines, which correlated well with proliferative 
responses.  
 
Cytokine production can be detected at the mRNA level with PCR or with in situ 
hybridization techniques. Intracellular cytokines can be detected by flow cytometry, 
whereas the detection of secreted cytokines often relies on enzyme-linked 
immunosorbent assay (ELISA)-based protocols254. In our studies we employed a bead-
based multiplex system carried out on the Luminex 100 technology platform, which 
measured the presence of cytokines in supernatants of cells. T cells were stimulated or 
not and supernatants were harvested after 48 hours and kept frozen at -70° C prior to 
analysis. Several populations of beads in suspension were each covalently linked to a 
unique antibody and could be separated from each other based on internal fluorescent 
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dyes. The beads could be mixed in the same assay allowing simultaneous detection of 
multiple cytokines. This system was chosen due to the relative ease by which a large 
number of samples could be analysed simultaneously for the presence of multiple 
cytokines. Detection of intracellular cytokines is superior in terms of identifying 
individual cytokine-producing cells, but does not provide a quantitative measure of 
actual cytokine secretion, which was most relevant in our study. Comparison of assays 
has shown high correlation between the detection of intracellular and secreted 
cytokines255. 
 
3.3 Human oligodendrocyte cell lines 
Two human oligodendrocyte cell lines, HOG and Human Oligos, were used to study the 
pathogenic potential of T cells. The HOG cell line is derived from an 
oligodendroglioma and expresses markers characteristic of immature oligodendrocytes, 
such as galactosyl cerebroside and CNPase256. The Hum Oligos is a cell line 
immortalized by the persistent infection of Bornea virus257. To induce differentiation of 
oligodendrocytes, cells were cultured in low serum conditions. This has previously been 
shown to enhance the expression of cell surface markers characteristic of mature 
oligodendrocytes and to increase susceptibility to apoptosis258. The use of differentiated 
cells was considered relevant because the majority of myelinating oligodendrocytes in 
the brain are terminally differentiated259,260. 
 
The two cell lines showed consistency in terms of growth rate and morphological 
appearance, and displayed comparable levels of apoptosis in response to T cells in in 
vitro assays. Immortalized cell lines may, however, respond differently to stress signals 
and cytokine milieu compared to cells in tissues or primary and short-term cell cultures, 
and results must be considered with this in mind. We did make an attempt to obtain 
oligodendrocytes from biopsy material, but were not successful. The use of 
immortalized cell lines in research is nevertheless a valuable tool for the investigation of 
cellular mechanisms. The ability to proliferate makes HOG and Human Oligos suitable 
for proliferation-based assays, such as the JAM assay employed in this study. Moreover, 
both HOG and Human Oligos have been employed in previous studies on the 
immunobiology of oligodendrocytes258,261.  
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3.3.1 Detection of apoptosis  
The interaction between T cells and oligodendrocytes was studied in a coculture system, 
and the JAM assay262 was employed to assess oligodendrocyte apoptosis. The JAM 
assay specifically measures the amount of DNA fragmentation, a hallmark of apoptosis, 
and represents a robust system for the detection of apoptosis. Oligodendrocytes were 
prelabeled with thymidine prior to T cell exposure. Washing steps removed fragmented 
DNA from the filter onto which the cell suspension was harvested. Apoptosis was then 
determined based on remaining intact DNA measured as counts per minute in a -plate 
liquid scintillation counter. The JAM assay was well suited for our coculture system as 
we could easily detect apoptosis of prelabeled oligodendrocytes without interference of 
apoptotic T cells present in the culture. As a validation of the JAM assay, annexin V 
positive oligodendrocytes could be detected by flow cytometry after coculture with T 
cells and confirmed that oligodendrocytes indeed died by apoptosis.  
 
3.4 Searching for target antigens of CSF mAbs 
Several attempts were made to identify potential target antigens for the two mAbs, CSF 
mAb1 and CSF mAb2. 
 
A multitude of candidate targets have been described for the Ig in the CSF of MS 
patients, including myelin proteins and viral proteins199,263. A first attempt to identify 
the specificity of the CSF mAbs was performed in an ELISA against MBP, B-
crystallin, cytomegalovirus, varicella-zoster virus, Borrelia burgdorferi, Toxoplasma 
gondii and EBV nuclear antigen. Furthermore, antibody reactivity against purified 
OMGP was tested in dot blot assays. 
 
Solid-phase assays may be better than solution-phase assays for the detection of low-
affinity interactions264. However, immobilization of antigens on a plastic surface or 
membrane may conceal critical epitopes or result in loss of epitopes due to 
denaturation265.  
 
A search for potential antigens in soluble phase was performed by using monodisperse 
magnetic particles (Dynabeads) coated with the CSF mAbs in immunoprecipitation 
assays. The surface tosyl groups allow covalent linking of antibodies via primary 
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amino- or sulphydryl groups and assure correct orientation of the antibodies to the bead 
surface. The beads were coated with CSF mAb1, CSF mAb2 or a control mAb in the 
presence of an alkaline buffer. Coated beads were incubated with cell lysate from 
differentiated HOG or Hum Oligos or lysate from human brain. Bound antigen was 
eluted from the beads by the use of an acidic buffer. Eluted proteins were visualized by 
gel electrophoresis and protein bands that differed between CSF mAbs and control 
mAbs were examined using mass spectrometry.  
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4. SUMMARY OF RESULTS 
 
Paper I:  
Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the 
cerebrospinal fluid. 
 
We investigated the presence and phenotype of GA reactive T cells from the CSF and 
blood in three short-time treated (3-6 months) RRMS patients before and after onset of 
GA treatment and in two patients who had been treated with GA for two and three 
years. From the short-time treated patients we established a total of 22 cell lines from 
the CSF and 36 cell lines from the blood before treatment, and 28 T cell lines from CSF 
and 31 T cell lines from blood during treatment. Ratios between pro-inflammatory 
cytokines (IFN- and TNF-) and anti-inflammatory cytokines (IL-5, IL-13 and IL-10) 
were used to define the phenotype of GA reactive T cells. The principal findings were: 
i) GA treatment induced an anti-inflammatory cytokine profile of GA reactive T cells 
from blood and CSF, and ii) following treatment, the anti-inflammatory shift was more 
pronounced for T cells present in the CSF compared to T cells present in the blood. A 
total of 20 GA specific T cell clones were generated from the two long-term treated 
patients. GA specific T cell clones and T cell lines were screened against recombinant 
human MBP and against 15-mer overlapping peptides spanning the complete sequences 
of MBP, PLP, MOG, MAG, OMGP, -cystallin, s100 and CNPase. No cross 
reactivity was detected. Four out of 10 GA reactive T cell clones from the CSF were 
restricted by HLA-DP whereas the remaining CSF T cell clones were restricted by 
HLA-DR molecules. All 10 GA reactive T cell clones from blood were restricted by 
HLA-DR molecules.  
 
Paper II:  
Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition 
of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. 
 
In this paper we generated two EBV-transformed CSF B cell lines from patients MS1 
and MS2 and two IgG1 mAbs were derived from the CSF B cell lines. Sequencing of 
the complimentary DNA encoding the V regions of the CSF mAbs revealed a ratio and 
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distribution of replacement to silent mutations suggesting that the B cells had undergone 
somatic hypermutation as part of a T cell dependent antigen-driven process in vivo. 
Attempts to identify the specificity of the CSF mAbs included ELISA against MBP, 
B-crystallin and several virus proteins, Western blotting against OMGP, and finally 
immunoprecipitation of lysate from human brain and human oligodendrocyte cell lines. 
No target antigen was identified. T cell lines and clones from CSF and blood of the two 
MS patients were found to recognize autologous, but not heterologous CSF mAbs. The 
T cell clones were CD4+ and responses were restricted by HLA-DR molecules. The T 
cell clones were found to be Th1 polarized and secreted predominantly IFN-. T cell 
responses were dependent on heat-aggregation of the CSF mAbs. Blocking of fragment 
crystallizable  receptors (FcRs) by preincubation of APCs with aggregated IgG from 
normal donors inhibited the response. CSF and blood T cell clones were tested against a 
panel of synthetic peptides spanning all amino acid replacements and CDR3s of the 
CSF mAbs. Two CSF T cell clones from one of the patients responded against a peptide 
from the FR, which contained two replacement mutations. For one of the CSF T cell 
clones the response was critically dependent on the mutations, as the T cell did not 
recognize the corresponding germline encoded peptide. The CSF T cell clones were 
found to secrete predominantly IFN-. 
 
Paper III:  
T cells from multiple sclerosis patients recognize multiple epitopes on self-IgG. 
 
The results in this paper extend the findings in paper II by showing that the idiotype of 
one single CSF mAb derived from an MS patient carries several antigenic Ids, which 
are able to elicit a broad polyclonal T cell response. PBMCs stimulated with synthetic 
peptides spanning the V regions of the CSF mAbs (the same peptide panel as that 
employed in paper II) showed strong proliferation against two VH and two VL peptides 
in patient MS1 and against two VH peptides in patient MS2. From the CSF of patient 
MS1 four T cell lines recognizing either a VL CDR3 peptide or a VH CDR1/FR2 
peptide were generated. From the blood of the same patient, six T cell lines recognizing 
the same VL CDR3 peptide, a VH FR3/CDR3 peptide or a VH FR1/CDR1/FR2 peptide 
were generated. T cell clones established from blood recognized a mutated VH 
FR1/CDR1/FR2 peptide (MS1-VH1) containing two amino acid substitutions compared 
to the germline encoded sequence. T cell responses were dependent on both mutations 
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as responses were lost when one or both mutations had been reverted to the germline 
encoded amino acids. The same T cell clones proliferated in response to HLA-matched 
PBMCs preincubated with high concentrations of CSF IgG (80-360 g/ml) overnight 
indicating that APCs process CSF IgG and present the MS1-VH1-peptide to Id-specific 
T cells. These T cell clones were CD4+ and restricted by HLA-DRB1*1302 encoded 
molecules. One T cell clone was shown to recognize both the mutated MS1-VH1-
peptide and the Id-bearing B cell clone suggesting that the B cells process and present 
Ids from its own BCR. The T cell clones were shown to secrete predominantly IFN-y.  
 
Paper IV:  
Idiotope-specific CD4+ T cells induce apoptosis of human oligodendrocytes. 
 
This study shows that Id-specific CD4+ T cells can induce apoptosis of 
oligodendrocytes in vitro. Two human oligodendrocyte cell lines were used to study the 
interaction between T cells and oligodendrocytes. Id-specific T cells stimulated either 
by Id-bearing B cells, by APCs preincubated with Id-peptides overnight or by anti-
CD3/anti-CD28 in the absence of accessory cells were shown to induce DNA 
fragmentation and killing of oligodendrocytes in an in vitro coculture system. The 
ability of the T cells to kill oligodendrocytes rapidly peaked upon their activation. 
Induction of apoptosis required contact between the T cells and the oligodendrocytes as 
no killing was observed when effector and target cells were separated by a transwell 
membrane (0.4 m pore size). Microscopy showed that activated T cells clustered 
around the oligodendrocyte cell body and lined up along its processes. 
Oligodendrocytes exposed to various concentrations and combinations of the pro-
inflammatory cytokines IFN- and TNF- showed no signs of apoptosis. Induction of 
oligodendrocyte apoptosis was independent of the T cells’ cytokine profile and required 
no cognate interaction between T cells and oligodendrocytes. Apoptosis could be 
inhibited by a general caspase inhibitor or by an anti-Fas mAb. Finally, T cells were 
shown to undergo apoptosis upon contact with oligodendrocytes.  
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5. GENERAL DISCUSSION 
 
A major part of the work in this thesis is based upon the study of B cells and T cells 
originating from the CSF. The underlying thought is that the CSF provides a “window 
to the brain” and that cells present in this compartment more accurately reflect the 
population of cells relevant for the disease process in MS than cells from blood. This is 
supported by observations in celiac disease showing that T cells from the gut display a 
more stringent HLA restriction pattern and recognize other antigens than T cells present 
in the blood266. As long as viable lymphocytes from MS lesions are not accessible, 
lymphocytes from the CSF were considered the best alternative in our study. 
 
The majority of lymphocytes in the CSF are CD4+ T cells of a memory phenotype, 
which most likely reflect the disease process. The population of disease relevant cells 
present in the CSF will be highly concentrated compared to disease relevant cells in the 
blood. Accordingly, when CSF fluid drains into the systemic circulation mononuclear 
cells present in the CSF will be diluted several 1000-fold making the disease relevant T 
cells in the blood difficult to detect. Comparison of T cells from blood and CSF can 
therefore point out important differences which may bear relevance for the disease 
process in CNS. 
 
5.1 The therapeutic potential of GA 
The entry of GA reactive T cells into the intrathecal compartment is considered a 
prerequisite for the therapeutic effect of GA reactive T cells230,245. GA is quickly 
degraded upon subcutaneous administration making it highly unlikely that it is present 
in the CNS in sufficiently high concentrations to have an immunologic effect267. Thus, 
GA reactive T cells which have been activated by GA experienced APCs outside of the 
CNS probably migrate to the CNS where they exert their therapeutic effect. Another 
possibility may be that GA experienced APCs migrate to the brain and stimulate T cells 
within the CNS217. Prior to our study, the ability of GA reactive T cells to access the 
brain had to some extent been established in mice230,231. The evidence for this in humans 
was limited to the observation that GA reactive T cells could migrate across an artificial 
BBB268. Our first question was therefore whether GA reactive T cells are present in the 
CSF. Our findings show that GA reactive T cells are present in blood and CSF both 
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prior to and after the onset of treatment, suggesting that GA reactivity exists 
independently of prior immunization. This is in agreement with other studies showing a 
high frequency of GA reactive T cells in treatment-naïve individuals as well as in the 
cord blood of newborns222,223,238. All T cell lines generated from both blood and CSF 
with primary GA stimulation were GA reactive. The low number of isolated CSF cells 
precludes direct calculation of the frequency of GA reactive T cells in the original 
sample. However, a rough estimate can be made based on the number of cells seeded 
per well and the resulting number of GA reactive T cell lines. Since the maximum 
number of CSF cells seeded per well was 5000 and all T cell lines turned out to be GA 
reactive, this suggests that the precursor frequency of GA reactive T cells in CSF both 
before and after initiation of GA treatment exceeded 1:5000. This frequency is much 
higher than normally observed with primary antigens and is more comparable to a recall 
response269.  
 
The daily subcutaneous injection of 20 mg GA is probably associated with an active 
priming of both naïve and memory T cells in secondary lymphoid organs. In agreement 
with several other studies222,223,238, we showed that GA treatment induced a shift in the 
cytokine profile of responding T cells towards an anti-inflammatory phenotype. Recent 
findings suggest that GA acts primarily on the APC population and that the effect on T 
cells may be secondary and dictated by the GA-induced cytokine profile of 
APCs217,220,221. When generating and testing T cell lines from patients before and after 
treatment, we used fresh autologous PBMCs as APCs and could therefore not separate 
the GA-induced effect on T cells from the effect on APCs. However, at least two 
observations indicate that there is a difference between GA reactive T cells in blood 
compared to CSF: i) the anti-inflammatory profile was more pronounced for T cells 
present in the CSF compared to T cell present in the blood, and ii) the GA induced shift 
towards a more anti-inflammatory phenotype was more pronounced in CSF than in 
blood, even though the same APCs were used in both blood and CSF. This suggests that 
in vivo peripheral priming of GA reactive T cells is followed by homing of a selected 
subset of GA reactive T cells to the intrathecal compartment. In addition, GA specific T 
cell clones from the CSF were restricted by either HLA-DR or HLA-DP molecules, 
whereas only HLA-DR restricted T cell clones were detected in the blood. This could be 
coincidental as only ten clones were investigated from each compartment, but is 
nevertheless remarkable as DP-restricted T cell clones have rarely been reported and to 
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our knowledge never in the context of GA reactivity. Thus, this finding may further 
suggest a difference between CSF cells and blood cells. 
 
Reactivation of GA reactive T cells in the brain by cross recognition of myelin proteins 
is one of the proposed mechanisms of action of GA and could potentially explain the 
recruitment of a selected population of GA reactive T cells into the intrathecal 
compartment229,231. Reports showing cross reactivity with myelin proteins have to the 
best of our knowledge only been investigated with the use of GA reactive T cell lines. 
By cloning GA reactive T cells we had for the first time the opportunity to investigate 
cross reactivity at clonal level with human T cells. Cross reactivity was tested against 
complete MBP protein and a panel of peptides that spanned the majority of the 
candidate autoantigens in MS. We were unable to detect cross reactivity for any of our 
T cell clones or lines, neither by proliferation nor by cytokine secretion. Our results 
cannot exclude the possibility that GA reactive T cells may cross recognize myelin 
proteins. Importantly, a limited number of clones were tested and we relied on secreted 
cytokines as this was considered most relevant, and did not attempt to detect changes in 
the pattern of intracellular cytokine production.  
 
The high frequency of GA reactive T cells in the blood and CSF of treatment-naïve 
individuals observed by us and others, and the demonstration that the majority of these 
are recruited from the memory pool of T cells223,238, suggest that GA mimics recall 
antigens to which the patient has been exposed previously. This is not unexpected 
considering the multitude of epitopes which may arise from the random composition of 
GA. Furthermore, the well-defined degeneracy of TCRs270,271 implies that a low level of 
random cross reactivity may be expected. Such random cross reactivity may account for 
reactivation of GA reactive cells in a variety of tissues and perhaps contribute to the 
therapeutic potential of GA in inflammatory diseases outside of the CNS272,273. Also, it 
may be hypothesized that a persistent inflammatory environment triggers a transient 
reactivation of GA reactive T cells in a TCR independent manner, which results in 
release of anti-inflammatory cytokines. This may contribute to bystander suppression of 
local inflammation in MS and other inflammatory diseases.  
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5.2 T cell responses to CSF IgG 
Paper II and III in this thesis describe T cell responses to Id present in CSF IgG. The 
foundation for this work was provided by the observation that MS patients display 
increased T cell responses to autologous IgG compared to patients with other 
neurological diseases159, which suggested that responses to IgG could be relevant for the 
disease process in MS. Paper II describes the establishment of EBV-transformed B cells 
and the purification of monoclonal CSF IgG from two MS patients, which greatly 
facilitated the study of T cell responses to IgG in the absence of potential contaminants. 
Strong proliferative T cell responses were recorded towards autologous, but not 
heterologous CSF mAbs in both MS patients. Based on the considerations mentioned 
for GA reactive T cell lines a similar estimate can be done for the frequency of CSF T 
cells recognizing CSF IgG. The overall frequency of CSF T cells recognizing CSF 
mAbs or CSF mAb peptides was thus estimated to be approximately 1:10000 or higher. 
This is a high frequency indicating that the CSF mAb responsive T cells were not 
recruited from the naïve repertoire, but rather represent memory T cells expanded 
during an in vivo immune response. Also supporting this was the ability to generate 
antigen-specific T cell lines with only one round of antigen stimulation and the vigorous 
proliferative responses observed in PBMCs. 
 
The accumulation and distribution of replacement to silent mutations in the V regions of 
the CSF mAbs suggest that the B cells had undergone somatic hypermutation during T 
cell dependent germinal center reactions. Somatic hypermutation is a hallmark of 
affinity-matured B cells both from the CSF182,183,186,189 and brain tissue of MS 
patients185,274, suggesting that the B cells producing the CSF mAbs are representative of 
disease relevant B cells in MS. The search for T cell epitopes in the CSF mAbs was 
restricted to regions containing amino acid substitutions and to the highly variable 
CDR3s. This was in part due to the shortage of CSF T cells and therefore a need to 
focus on the most probable immunogenic determinants. T cell responses to Ig in other 
model systems have consistently shown that amino acid substitutions are essential for 
the immunogenicity of Ids and that T cells generally are tolerant towards germline 
encoded sequences61,275,276. In agreement with this, our study shows that T cell 
responses to a mutated peptide containing two replacement mutations were lost when 
the amino acid substitutions were reverted to the germline encoded amino acids. 
However, most of the CSF mAb responsive T cell clones did not recognize any of the 
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mutated peptides. This may suggest that they were specific for epitopes located outside 
of the sequences covered by the peptide panel employed in this study. Supporting this is 
the observation that germline encoded IgM has been shown to be immunogenic in 
syngeneic mice277. An alternative explanation is that the number of peptides was too 
small to ensure correct positioning of the mutated amino acids in relation to MHC 
binding and T cell recognition.  
 
The finding of T cell responses directed against several Ids in the V region of one CSF 
mAb is compatible with a diversification of the immune response through the process of 
epitope spreading (paper III). Epitope spreading is a typical feature of chronic immune 
responses and is defined as the dissemination of epitope specificity from an initial 
dominant epitope to subdominant or cryptic ones278. This is thought to be important in 
the progression of EAE and Theiler’s murine encephalomyelitis278. Furthermore, 
epitope spreading to Ids on autoantibodies is thought to be important in experimental 
lupus279. Epitope spreading is, however, difficult to verify in human disease because the 
identity of the initiating epitope is hard to determine.  
 
CD4+ T cells can only respond to Ids when presented in combination with MHC class II 
molecules. Microglia and blood derived DCs are present in active MS lesions128 and 
may present Id to Id-specific T cell in vivo. Paper II shows that T cell responses to CSF 
mAbs are dependent on FcR mediated uptake and required prior heat aggregation of 
the IgG molecules. This may raise a concern regarding the immunogenicity of single 
soluble IgG molecules. However, antibodies in the CSF of MS patients have been 
shown to form immune complexes280, and strong upregulation of FcR I, II and III on 
microglia in MS lesions suggests that facilitated uptake of IgG may occur in MS281. 
Moreover, Id-specific T cells may become activated by Id-bearing B cells. Thus, B cells 
constitutively process and present peptide fragments from their endogenous BCRs in 
combination with MHC class II and can activate Id-specific T cells that are specific for 
rare Id sequences26. In this study we show that autologous B cells from the CSF have 
the capacity to specifically activate an Id-specific T cell clone. This was demonstrated 
by incubating Id-specific T cells in the presence of Id-bearing and several non-Id-
bearing EBV-transformed B cell lines, and by inhibiting the response with anti-HLA-
DR antibodies (Paper III and IV).  
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The observation that the CSF mAb1 and 2 are IgG with a high ratio of silent to 
replacement mutations suggests that the B cells producing these mAbs had been subject 
to somatic hypermutation in a T cell driven germinal center reaction. Studies on Id-
driven T-B cell collaboration in mice have shown that ligation of the BCR may be 
necessary for isotype switching and affinity maturation to occur66. It was therefore of 
interest to search for potential CNS targets of the CSF mAbs. However, we have not 
been able to identify the target for any of our CSF mAbs, despite several attempts 
employing both solution-phase and solid-phase assays (Paper II). The potential 
pathogenic effect of the CSF mAbs was also tested in vivo by Claudia Sommers’ 
research group in Wuerzburg, Germany. Here, the CSF mAbs were injected into the 
intrathecal compartment of rats, which were monitored for signs of EAE. Injected 
animals displayed no clinical signs of neurological disease and no signs of 
immunoreactivity in slices of brain or spinal cord. Also, no specific binding was 
detected when the CSF mAbs were incubated with brain or spinal cord tissue from 
human, rat or mouse. It is, however, fully possible that the CSF mAbs target other 
antigens, such as inflammation-induced proteins or infectious agents that have not been 
tested by us or our collaborators. 
 
Another possibility that may explain the failure to identify target antigens for the CSF 
mAbs is that they display very low affinity or have lost affinity for the original antigen. 
B cells that loose their affinity during affinity maturation will normally not be selected 
and die from apoptosis282. However, such B cells may be rescued if a loss-of-affinity 
mutation creates an Id-peptide recognized by germinal center Id-specific T cells. This 
appeared to be the case for a dominant chromatin specific B cell clone associated with 
the induction of experimental lupus283. Two replacement mutations in FR1 and CDR2 
were traced back to the original single precursor cell giving rise to the B cell clone. 
None of these mutations were shown to increase the binding affinity for the antigen, but 
instead created an immunodominant epitope recognized by MHC class II restricted Id-
specific T cells. Mutations in the FR usually do not confer stronger binding affinity, but 
rather lead to detrimental structural changes in the antibody molecule and are therefore 
not prone to be selected284. It was therefore hypothesized that the FR mutation had 
created an immunogenic Id, which selected the B cell due to its receptor presentation 
capabilities instead of increased affinity for an antigen283. In support of such processes 
also playing a role in the maturation of the Id-bearing B cells in our study155, we 
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encountered an Id-specific T cell clone that recognized an Id located in the FR of the 
CSF mAb (paper II). If low affinity B cells are really rescued in such a process, it may 
explain the difficulties in identifying the target antigen of the CSF mAbs. Moreover, an 
intrathecal B cell response sustained by Id-specific T cells may offer an explanation for 
the persistent production of both the main oligoclonal IgG of unknown specificity and 
the virus-specific antibodies in the CSF of MS patients. 
 
In paper IV we demonstrate that CD4+ Id-specific T cells induce apoptosis of 
oligodendrocytes, suggesting a potential role of Id-specific T cells in MS pathogenesis. 
The relevance of apoptosis as a result of T cell mediated inflammation in MS has been 
debated. Two of four patterns of demyelination which were identified in autopsies and 
biopsies from 83 MS patients suggested T cell mediated inflammation as a secondary 
event to primary myelin damage285. Also, apoptosis of oligodendrocytes was observed 
in the absence of T cell infiltration in patients who died of acute MS286. However, 
biopsy and autopsy material from acute or lethal MS may not be fully representative for 
common MS. Moreover, it is possible that T cell mediated apoptosis of 
oligodendrocytes may prevail during a short time span in early stages of MS and be less 
apparent in late stages of the disease286,287.  
 
Inflamed brain endothelium upregulates expression of adhesion molecules, which allow 
entrance of CD4+ T cells into the CNS irrespective of antigen-specificity109. It is 
believed that only those T cells that recognize their cognate antigen will be retained and 
expanded intrathecally110. Accordingly, CD4+ T cells without specificity for any CNS 
antigen have been shown to enter the brain, but caused no damage to glial cells288. 
Importantly, the B cells producing Id-bearing mAbs were derived from the intrathecal 
compartment. Thus, Id-specific T cells may be pathogenic in MS because they may be 
activated and retained intrathecally when encountering CNS residing Id-bearing B cells.  
 
We chose a reductionistic approach and studied the potential pathogenic effect of Id-
specific T cells towards oligodendrocytes in the absence of accessory cells. It is possible 
that direct killing of oligodendrocytes by T cells mainly is an in vitro phenomenon and 
perhaps not as relevant in vivo. Indeed, differences between in vitro and in vivo systems 
have been demonstrated for the killing of Id-bearing myeloma cells by Id-specific T 
cells in mice. While in vitro killing was mediated by Fas/Fas ligand interactions289, 
killing in vivo was dependent on macrophages activated by T cell derived IFN-290. 
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Macrophage activation was also apparent during inflammatory responses associated 
with Id-driven T-B cell collaboration in mice291. This implies that the cytokine profile of 
T cells may be critical in vivo in contrast to our findings where both Th2-polarized GA 
reactive T cells and Th1-polarized T cells killed oligodendrocytes with equal efficiency. 
Lastly, establishment of T-B cell interaction in vivo may recruit other inflammatory 
cells and direct killing of oligodendrocytes by T cells may be only one of several 
mechanisms operative in vivo. 
 
5.2.1 A hypothesis on Id-driven T-B cell collaboration in MS  
Oligoclonal expansion of T cells and B cells with unknown antigen specificity is a 
prominent feature of MS164,182,184,188. We have shown that B cells, which bear 
similarities to clonally expanded B cells in the CSF of MS patients, carry several 
immunogenic Ids. The high frequency of Id-reactive T cells in the CSF and the 
observation that Id-bearing B cells and Id-specific T cells may reciprocally activate and 
sustain each other66 suggest that Id-driven T-B cell collaboration may contribute to the 
intrathecal immune response in MS. In this context it is interesting to note the finding of 
B cell follicles in the brain of MS patients206 and the clinical benefit of B cell 
depletion209 that in a new way have underscored the importance of B cells in the 
pathogenesis of MS.  
 
Based on the concept of Id-driven T-B cell collaboration and the observations on this 
phenomenon made by us and others, the following scenario may be proposed155: The 
initial trigger of MS could be an infectious agent that leads to germinal center reactions 
in secondary lymphoid organs and triggers activation of T and B cells. During the 
process of affinity maturation, somatic hypermutation creates immunogenic Ids, which 
are recognized by Id-specific T cells. Id-bearing B cells and Id-specific T cells may by 
chance re-encounter in the CNS, resulting in Id-driven T-B cell collaboration and the 
establishment of inflammatory foci. Id-specific T cell activation may lead to unspecific 
bystander killing of oligodendrocytes and other CNS cells (Figure 3). This model could 
explain the persistent cellular and humoral immune response in the CNS and the 
ongoing inflammation in MS in the absence of a conventional target antigen. It may 
explain how normal immune responses against infectious agents may eventually lead to 
an immune mediated disease in the brain. Moreover, this model does not have to imply 
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breaking of tolerance against self-molecules, as Id-specific T cells target an 
immunological “non-self” on a self-molecule.  
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Figure 3. A schematic view of Id-driven T-B cell collaboration in MS. Id-specific T 
cells and Id-bearing B cells activated during germinal center reactions in peripheral 
lymphoid organs may re-encounter intrathecally. Reactivation may lead to 
establishment of inflammatory foci with a T cell sustained differentiation of the B cell 
into an Ig-secreting plasma cell and stimulation of T cell effector mechanisms. The Ig 
may be a source of OCBs in MS and Id-specific T cells may induce apoptosis of 
oligodendrocytes via Fas/Fas ligand interactions. 
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6. FUTURE STUDIES 
 
6.1 Id-driven T-B cell collaboration in MS  
The results presented in this thesis suggest that Id-driven T-B cell collaboration may 
contribute to the immune mediated plaque-wise destruction of the CNS. However, as all 
results are based on in vitro observations on a limited number of cells from two MS 
patients, they may not bear relevance in vivo. To approach this issue, a modified model 
of the previously mentioned transgenic mice expressing Id+ B cells and the 
corresponding Id-specific TCR will be employed69. The new model includes an NF-B-
responsive luciferase reporter transgene, which allows in vivo visualization of 
inflammation in addition to clinical recordings and conventional histopathologic 
studies292. We wish to use this system to examine whether T-B cell collaboration in the 
brain correlates with the development of neurological symptoms and MS-like disease. 
In support of this, four animals out of about 200 of the double transgenic mice did 
develop signs of neurological disease with partial hind limb paralysis, suggestive of 
CNS inflammation (personal communication L. Munthe, Rikshospitalet University 
Hospital). 
 
6.2 Production of growth factors by GA reactive T cells 
With the establishment of GA reactive T cell clones from the CSF and blood of GA 
treated patients we have the possibility to assess the secretion of growth factors at a 
clonal level and compare GA reactive cells from the CSF and blood with T cells of 
other specificities. So far, we have tested BDNF secretion by two GA specific T cell 
clones from the CSF stimulated by GA in the presence of autologous PBMCs or by anti-
CD3/anti-CD28 antibodies. Preliminary results indicate that production of BDNF was 
mainly a feature of PBMCs as no BDNF was detected in the supernatant of anti-
CD3/anti-CD28 stimulated T cell clones in the absence of accessory cells.  
 
 
                          
 51
7. REFERENCES
 
 1.  Medzhitov R and Janeway CA Jr. Innate immune recognition and control of 
adaptive immune responses. Semin. Immunol. 1998; 10: 351-353. 
 2.  Janeway CA Jr. Approaching the asymptote? Evolution and revolution in 
immunology. Cold Spring Harb. Symp. Quant. Biol. 1989; 54 Pt 1: 1-13. 
 3.  Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 
301-305. 
 4.  Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat. 
Immunol. 2007; 8: 11-13. 
 5.  Kisielow P, Teh HS, Bluthmann H and von Boehmer H. Positive selection of 
antigen-specific T cells in thymus by restricting MHC molecules. Nature 1988; 
335: 730-733. 
 6.  Goldrath AW and Bevan MJ. Selecting and maintaining a diverse T-cell 
repertoire. Nature 1999; 402: 255-262. 
 7.  von Boehmer H, Aifantis I, Gounari F, et al. Thymic selection revisited: how 
essential is it? Immunol. Rev. 2003; 191: 62-78. 
 8.  Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. 
Annu. Rev. Immunol. 2001; 19: 375-396. 
 9.  Lanzavecchia A and Sallusto F. Dynamics of T lymphocyte responses: 
intermediates, effectors, and memory cells. Science 2000; 290: 92-97. 
 10.  Sallusto F and Lanzavecchia A. Exploring pathways for memory T cell 
generation. J. Clin. Invest 2001; 108: 805-806. 
 11.  Stemberger C, Huster KM, Koffler M, et al. A single naive CD8+ T cell 
precursor can develop into diverse effector and memory subsets. Immunity. 
2007; 27: 985-997. 
 12.  Bushar ND and Farber DL. Recalling the year in memory T cells. Ann. N. Y. 
Acad. Sci. 2008; 1143: 212-225. 
 13.  Early P, Rogers J, Davis M, et al. Two mRNAs can be produced from a single 
immunoglobulin mu gene by alternative RNA processing pathways. Cell 1980; 
20: 313-319. 
 14.  Harris LJ, Larson SB, Hasel KW, et al. The three-dimensional structure of an 
intact monoclonal antibody for canine lymphoma. Nature 1992; 360: 369-372. 
 15.  Melchers F, Rolink A, Grawunder U, et al. Positive and negative selection 
events during B lymphopoiesis. Curr. Opin. Immunol. 1995; 7: 214-227. 
 52
 16.  Valle A, Zuber CE, Defrance T, et al. Activation of human B lymphocytes 
through CD40 and interleukin 4. Eur. J. Immunol. 1989; 19: 1463-1467. 
 17.  Lane P, Traunecker A, Hubele S, et al. Activated human T cells express a ligand 
for the human B cell-associated antigen CD40 which participates in T cell-
dependent activation of B lymphocytes. Eur. J. Immunol. 1992; 22: 2573-2578. 
 18.  Griffiths GM, Berek C, Kaartinen M and Milstein C. Somatic mutation and the 
maturation of immune response to 2-phenyl oxazolone. Nature 1984; 312: 271-
275. 
 19.  Berek C, Griffiths GM and Milstein C. Molecular events during maturation of 
the immune response to oxazolone. Nature 1985; 316: 412-418. 
 20.  Neuberger MS and Milstein C. Somatic hypermutation. Curr. Opin. Immunol. 
1995; 7: 248-254. 
 21.  Bernasconi NL, Traggiai E and Lanzavecchia A. Maintenance of serological 
memory by polyclonal activation of human memory B cells. Science 2002; 298: 
2199-2202. 
 22.  Kunkel HG, Mannik M and Williams RC. Individual Antigenic Specificity of 
Isolated Antibodies. Science 1963; 140: 1218-1219. 
 23.  Oudin J and Michel M. [A new allotype form of rabbit serum gamma-globulins, 
apparently associated with antibody function and specificity.]. C. R. Hebd. 
Seances Acad. Sci. 1963; 257: 805-808. 
 24.  Jerne NK. Towards a network theory of the immune system. Ann. Immunol. 
(Paris) 1974; 125C: 373-389. 
 25.  Janeway CA Jr., Sakato N and Eisen HN. Recognition of immunoglobulin 
idiotypes by thymus-derived lymphocytes. Proc. Natl. Acad. Sci. U. S. A 1975; 
72: 2357-2360. 
 26.  Bogen B and Weiss S. Processing and presentation of idiotypes to MHC-
restricted T cells. Int. Rev. Immunol. 1993; 10: 337-355. 
 27.  Eisen HN, Simms ES and Potter M. Mouse myeloma proteins with antihapten 
antibody acitivity. The protein produced by plasma cell tumor MOPC-315. 
Biochemistry 1968; 7: 4126-4134. 
 28.  Lynch RG, Graff RJ, Sirisinha S, Simms ES and Eisen HN. Myeloma proteins 
as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. U. S. A 1972; 
69: 1540-1544. 
 29.  Cosenza H. Detection of anti-idiotype reactive cells in the response to 
phosphorylcholine. Eur. J. Immunol. 1976; 6: 114-116. 
 30.  Schrater AF, Goidl EA, Thorbecke GJ and Siskind GW. Production of auto-anti-
idiotypic antibody during the normal immune response to TNP-ficoll. III. 
 53
Absence in nu/nu mice: evidence for T-cell dependence of the anti-idiotypic-
antibody response. J. Exp. Med. 1979; 150: 808-817. 
 31.  Jorgensen T and Hannestad K. Specificity of T and B lymphocytes for myeloma 
protein 315. Eur. J. Immunol. 1977; 7: 426-431. 
 32.  Jorgensen T and Hannestad K. H--2-linked genes control immune response to V-
domains of myeloma protein 315. Nature 1980; 288: 396-397. 
 33.  Bogen B, Jorgensen T and Hannestad K. T helper cell recognition of idiotopes 
on lambda 2 light chains of M315 and T952: evidence for dependence on 
somatic mutations in the third hypervariable region. Eur. J. Immunol. 1985; 15: 
278-281. 
 34.  Lauritzsen GF, Weiss S, Dembic Z and Bogen B. Naive idiotype-specific CD4+ 
T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. U. S. A 
1994; 91: 5700-5704. 
 35.  Dembic Z, Schenck K and Bogen B. Dendritic cells purified from myeloma are 
primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc. 
Natl. Acad. Sci. U. S. A 2000; 97: 2697-2702. 
 36.  Bogen B, Ruffini PA, Corthay A, et al. Idiotype-specific immunotherapy in 
multiple myeloma: suggestions for future directions of research. Haematologica 
2006; 91: 941-948. 
 37.  Ben-Nun A, Wekerle H and Cohen IR. Vaccination against autoimmune 
encephalomyelitis with T-lymphocyte line cells reactive against myelin basic 
protein. Nature 1981; 292: 60-61. 
 38.  Lider O, Reshef T, Beraud E, Ben-Nun A and Cohen IR. Anti-idiotypic network 
induced by T cell vaccination against experimental autoimmune 
encephalomyelitis. Science 1988; 239: 181-183. 
 39.  Vandenbark AA and Abulafia-Lapid R. Autologous T-cell vaccination for 
multiple sclerosis: a perspective on progress. BioDrugs. 2008; 22: 265-273. 
 40.  Zhang JZ, Rivera VM, Tejada-Simon MV, et al. T cell vaccination in multiple 
sclerosis: results of a preliminary study. J. Neurol. 2002; 249: 212-218. 
 41.  Medaer R, Stinissen P, Truyen L, Raus J and Zhang J. Depletion of myelin-
basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple 
sclerosis. Lancet 1995; 346: 807-808. 
 42.  Hermans G, Denzer U, Lohse A, Raus J and Stinissen P. Cellular and humoral 
immune responses against autoreactive T cells in multiple sclerosis patients after 
T cell vaccination. J. Autoimmun. 1999; 13: 233-246. 
 43.  Shoenfeld Y and Mozes E. Pathogenic idiotypes of autoantibodies in 
autoimmunity: lessons from new experimental models of SLE. FASEB J. 1990; 
4: 2646-2651. 
 54
 44.  Isenberg DA, Shoenfeld Y, Madaio MP, et al. Anti-DNA antibody idiotypes in 
systemic lupus erythematosus. Lancet 1984; 2: 417-422. 
 45.  Mendlovic S, Segal R, Shoenfeld Y and Mozes E. Anti-DNA idiotype- and anti-
idiotype-specific T cell responses in patients with systemic lupus erythematosus 
and their first-degree relatives. Clin. Exp. Immunol. 1990; 82: 504-508. 
 46.  Mendlovic S, Brocke S, Shoenfeld Y, et al. Induction of a systemic lupus 
erythematosus-like disease in mice by a common human anti-DNA idiotype. 
Proc. Natl. Acad. Sci. U. S. A 1988; 85: 2260-2264. 
 47.  Singh RR, Ebling FM, Sercarz EE and Hahn BH. Immune tolerance to 
autoantibody-derived peptides delays development of autoimmunity in murine 
lupus. J. Clin. Invest 1995; 96: 2990-2996. 
 48.  Ebling FM, Tsao BP, Singh RR, Sercarz E and Hahn BH. A peptide derived 
from an autoantibody can stimulate T cells in the (NZB x NZW)F1 mouse 
model of systemic lupus erythematosus. Arthritis Rheum. 1993; 36: 355-364. 
 49.  Singh RR, Kumar V, Ebling FM, et al. T cell determinants from autoantibodies 
to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. 
J. Exp. Med. 1995; 181: 2017-2027. 
 50.  Zinger H, Eilat E, Meshorer A and Mozes E. Peptides based on the 
complementarity-determining regions of a pathogenic autoantibody mitigate 
lupus manifestations of (NZB x NZW)F1 mice via active suppression. Int. 
Immunol. 2003; 15: 205-214. 
 51.  Waisman A, Ruiz PJ, Israeli E, et al. Modulation of murine systemic lupus 
erythematosus with peptides based on complementarity determining regions of a 
pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A 1997; 
94: 4620-4625. 
 52.  Eilat E, Dayan M, Zinger H and Mozes E. The mechanism by which a peptide 
based on complementarity-determining region-1 of a pathogenic anti-DNA auto-
Ab ameliorates experimental systemic lupus erythematosus. Proc. Natl. Acad. 
Sci. U. S. A 2001; 98: 1148-1153. 
 53.  Sela U, Sharabi A, Dayan M, Hershkoviz R and Mozes E. The role of dendritic 
cells in the mechanism of action of a peptide that ameliorates lupus in murine 
models. Immunology 2008. PMID: 19040426 
 54.  Eyerman MC and Wysocki L. T cell recognition of somatically-generated Ab 
diversity. J. Immunol. 1994; 152: 1569-1577. 
 55.  Eyerman MC, Zhang X and Wysocki LJ. T cell recognition and tolerance of 
antibody diversity. J. Immunol. 1996; 157: 1037-1046. 
 56.  Rudensky AY, Preston-Hurlburt P, al-Ramadi BK, Rothbard J and Janeway CA 
Jr. Truncation variants of peptides isolated from MHC class II molecules suggest 
sequence motifs. Nature 1992; 359: 429-431. 
 55
 57.  Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among 
naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 1993; 178: 
27-47. 
 58.  Vartdal F, Johansen BH, Friede T, et al. The peptide binding motif of the disease 
associated HLA-DQ (alpha 1* 0501, beta 1* 0201) molecule. Eur. J. Immunol. 
1996; 26: 2764-2772. 
 59.  Weiss S and Bogen B. MHC class II-restricted presentation of intracellular 
antigen. Cell 1991; 64: 767-776. 
 60.  Eynon EE and Parker DC. Small B cells as antigen-presenting cells in the 
induction of tolerance to soluble protein antigens. J. Exp. Med. 1992; 175: 131-
138. 
 61.  Bogen B, Malissen B and Haas W. Idiotope-specific T cell clones that recognize 
syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. 
Immunol. 1986; 16: 1373-1378. 
 62.  Bogen B, Snodgrass R, Briand JP and Hannestad K. Synthetic peptides and beta-
chain gene rearrangements reveal a diversified T cell repertoire for a lambda 
light chain third hypervariable region. Eur. J. Immunol. 1986; 16: 1379-1384. 
 63.  Yamamoto H, Araki K, Bitoh S, et al. Cytotoxic T lymphocyte clone 
recognizing self idiotype: its regulatory role in antibody production. Eur. J. 
Immunol. 1987; 17: 719-722. 
 64.  Chakrabarti D and Ghosh SK. Induction of syngeneic cytotoxic T lymphocytes 
against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed 
form(s) of idiotype. Cell Immunol. 1992; 144: 455-464. 
 65.  Weiss S and Bogen B. B-lymphoma cells process and present their endogenous 
immunoglobulin to major histocompatibility complex-restricted T cells. Proc. 
Natl. Acad. Sci. U. S. A 1989; 86: 282-286. 
 66.  Munthe LA, Os A, Zangani M and Bogen B. MHC-restricted Ig V region-driven 
T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG 
production. J. Immunol. 2004; 172: 7476-7484. 
 67.  Snyder CM, Aviszus K, Heiser RA, et al. Activation and tolerance in CD4(+) T 
cells reactive to an immunoglobulin variable region. J. Exp. Med. 2004; 200: 1-
11. 
 68.  Zangani MM, Froyland M, Qiu GY, et al. Lymphomas can develop from B cells 
chronically helped by idiotype-specific T cells. J. Exp. Med. 2007; 204: 1181-
1191. 
 69.  Munthe LA, Corthay A, Os A, Zangani M and Bogen B. Systemic autoimmune 
disease caused by autoreactive B cells that receive chronic help from Ig V 
region-specific T cells. J. Immunol. 2005; 175: 2391-2400. 
 56
 70.  Mendlovic S, Shoenfeld Y, Bakimer R, et al. In vitro T-cell functions specific to 
an anti-DNA idiotype and serological markers in patients with systemic lupus 
erythematosus (SLE). J. Clin. Immunol. 1988; 8: 178-187. 
 71.  Schwartz RS and Stollar BD. Origins of anti-DNA autoantibodies. J. Clin. Invest 
1985; 75: 321-327. 
 72.  Dayan M, Segal R, Sthoeger Z, et al. Immune response of SLE patients to 
peptides based on the complementarity determining regions of a pathogenic anti-
DNA monoclonal antibody. J. Clin. Immunol. 2000; 20: 187-194. 
 73.  Sthoeger ZM, Dayan M, Tcherniack A, et al. Modulation of autoreactive 
responses of peripheral blood lymphocytes of patients with systemic lupus 
erythematosus by peptides based on human and murine anti-DNA 
autoantibodies. Clin. Exp. Immunol. 2003; 131: 385-392. 
 74.  van Schooten WC, Devereux D, Ho CH, et al. Joint-derived T cells in 
rheumatoid arthritis react with self-immunoglobulin heavy chains or 
immunoglobulin-binding proteins that copurify with immunoglobulin. Eur. J. 
Immunol. 1994; 24: 93-98. 
 75.  Powell TJ, Quan J, Freund E and van Schooten WCA. Activation of T Cells by 
Autoantigen Immobilized by Specific Antibodies. Methods 1996; 9: 453-457. 
 76.  Laufer TM, DeKoning J, Markowitz JS, Lo D and Glimcher LH. Unopposed 
positive selection and autoreactivity in mice expressing class II MHC only on 
thymic cortex. Nature 1996; 383: 81-85. 
 77.  Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody 
production by early human B cell precursors. Science 2003; 301: 1374-1377. 
 78.  Bouneaud C, Kourilsky P and Bousso P. Impact of negative selection on the T 
cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes 
clonal deletion. Immunity. 2000; 13: 829-840. 
 79.  Liu GY, Fairchild PJ, Smith RM, et al. Low avidity recognition of self-antigen 
by T cells permits escape from central tolerance. Immunity. 1995; 3: 407-415. 
 80.  Danke NA, Koelle DM, Yee C, Beheray S and Kwok WW. Autoreactive T cells 
in healthy individuals. J. Immunol. 2004; 172: 5967-5972. 
 81.  Krogsgaard M, Juang J and Davis MM. A role for "self" in T-cell activation. 
Semin. Immunol. 2007; 19: 236-244. 
 82.  DeJong BA and Smith ME. A role for complement in phagocytosis of myelin. 
Neurochem. Res. 1997; 22: 491-498. 
 83.  Ragazzo JL, Ozaki ME, Karlsson L, Peterson PA and Webb SR. Costimulation 
via lymphocyte function-associated antigen 1 in the absence of CD28 ligation 
promotes anergy of naive CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A 2001; 98: 
241-246. 
 57
 84.  Powell JD, Ragheb JA, Kitagawa-Sakakida S and Schwartz RH. Molecular 
regulation of interleukin-2 expression by CD28 co-stimulation and anergy. 
Immunol. Rev. 1998; 165: 287-300. 
 85.  Harding FA, McArthur JG, Gross JA, Raulet DH and Allison JP. CD28-
mediated signalling co-stimulates murine T cells and prevents induction of 
anergy in T-cell clones. Nature 1992; 356: 607-609. 
 86.  Moalem G, Leibowitz-Amit R, Yoles E, et al. Autoimmune T cells protect 
neurons from secondary degeneration after central nervous system axotomy. 
Nat. Med. 1999; 5: 49-55. 
 87.  Hauben E, Butovsky O, Nevo U, et al. Passive or active immunization with 
myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 
2000; 20: 6421-6430. 
 88.  Kipnis J, Mizrahi T, Hauben E, et al. Neuroprotective autoimmunity: naturally 
occurring CD4+CD25+ regulatory T cells suppress the ability to withstand 
injury to the central nervous system. Proc. Natl. Acad. Sci. U. S. A 2002; 99: 
15620-15625. 
 89.  Cameron HA and McKay RD. Adult neurogenesis produces a large pool of new 
granule cells in the dentate gyrus. J. Comp Neurol. 2001; 435: 406-417. 
 90.  Alvarez-Buylla A and Garcia-Verdugo JM. Neurogenesis in adult subventricular 
zone. J. Neurosci. 2002; 22: 629-634. 
 91.  Ziv Y, Ron N, Butovsky O, et al. Immune cells contribute to the maintenance of 
neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006; 9: 
268-275. 
 92.  Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated 
homologous macrophages results in partial recovery of paraplegic rats. Nat. 
Med. 1998; 4: 814-821. 
 93.  Butovsky O, Hauben E and Schwartz M. Morphological aspects of spinal cord 
autoimmune neuroprotection: colocalization of T cells with B7--2 (CD86) and 
prevention of cyst formation. FASEB J. 2001; 15: 1065-1067. 
 94.  Butovsky O, Ziv Y, Schwartz A, et al. Microglia activated by IL-4 or IFN-
gamma differentially induce neurogenesis and oligodendrogenesis from adult 
stem/progenitor cells. Mol. Cell Neurosci. 2006; 31: 149-160. 
 95.  Belmadani A, Tran PB, Ren D and Miller RJ. Chemokines regulate the 
migration of neural progenitors to sites of neuroinflammation. J. Neurosci. 2006; 
26: 3182-3191. 
 96.  Ziv Y, Avidan H, Pluchino S, Martino G and Schwartz M. Synergy between 
immune cells and adult neural stem/progenitor cells promotes functional 
recovery from spinal cord injury. Proc. Natl. Acad. Sci. U. S. A 2006; 103: 
13174-13179. 
 58
 97.  Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B 
cells, and monocytes produce brain-derived neurotrophic factor in vitro and in 
inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. 
Med. 1999; 189: 865-870. 
 98.  Burns JB, Bartholomew BD and Lobo ST. In vivo activation of myelin 
oligodendrocyte glycoprotein-specific T cells in healthy control subjects. Clin. 
Immunol. 2002; 105: 185-191. 
 99.  Marrack P, Kappler J and Kotzin BL. Autoimmune disease: why and where it 
occurs. Nat. Med. 2001; 7: 899-905. 
 100.  Whitacre CC. Sex differences in autoimmune disease. Nat. Immunol. 2001; 2: 
777-780. 
 101.  Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple 
autoimmune disease genetics consortium (MADGC) collection: the PTPN22 
620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. 
Genet. 2005; 76: 561-571. 
 102.  Mackay IR, Leskovsek NV and Rose NR. Cell damage and autoimmunity: a 
critical appraisal. J. Autoimmun. 2008; 30: 5-11. 
 103.  Guilherme L, Ramasawmy R and Kalil J. Rheumatic fever and rheumatic heart 
disease: genetics and pathogenesis. Scand. J. Immunol. 2007; 66: 199-207. 
 104.  Yuki N. Current cases in which epitope mimicry is considered a component 
cause of autoimmune disease: Guillain-Barre syndrome. Cell Mol. Life Sci. 
2000; 57: 527-533. 
 105.  Ransohoff RM, Kivisakk P and Kidd G. Three or more routes for leukocyte 
migration into the central nervous system. Nat. Rev. Immunol. 2003; 3: 569-
581. 
 106.  Strazielle N and Ghersi-Egea JF. Choroid plexus in the central nervous system: 
biology and physiopathology. J. Neuropathol. Exp. Neurol. 2000; 59: 561-574. 
 107.  Johanson CE, Duncan JA, III, Klinge PM, et al. Multiplicity of cerebrospinal 
fluid functions: New challenges in health and disease. Cerebrospinal. Fluid Res. 
2008; 5: 10. 
 108.  Szentistvanyi I, Patlak CS, Ellis RA and Cserr HF. Drainage of interstitial fluid 
from different regions of rat brain. Am. J. Physiol 1984; 246: F835-F844. 
 109.  Wekerle H, Sun D, Oropeza-Wekerle RL and Meyermann R. Immune reactivity 
in the nervous system: modulation of T-lymphocyte activation by glial cells. J. 
Exp. Biol. 1987; 132: 43-57. 
 110.  Hickey WF, Hsu BL and Kimura H. T-lymphocyte entry into the central nervous 
system. J. Neurosci. Res. 1991; 28: 254-260. 
 59
 111.  Kivisakk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central 
memory CD4+ T cells: evidence for trafficking through choroid plexus and 
meninges via P-selectin. Proc. Natl. Acad. Sci. U. S. A 2003; 100: 8389-8394. 
 112.  Weller RO. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: 
significance for Alzheimer disease, prion disorders and multiple sclerosis. J. 
Neuropathol. Exp. Neurol. 1998; 57: 885-894. 
 113.  Perry VH. A revised view of the central nervous system microenvironment and 
major histocompatibility complex class II antigen presentation. J. 
Neuroimmunol. 1998; 90: 113-121. 
 114.  Aloisi F, Ria F and Adorini L. Regulation of T-cell responses by CNS antigen-
presenting cells: different roles for microglia and astrocytes. Immunol. Today 
2000; 21: 141-147. 
 115.  Waksman BH and Dams RD. A histologic study of the early lesion in 
experimental allergic encephalomyelitis in the guinea pig and rabbit. Am. J. 
Pathol. 1962; 41: 135-162. 
 116.  Lassmann H and Wisniewski HM. Chronic relapsing EAE. Time course of 
neurological symptoms and pathology. Acta Neuropathol. 1978; 43: 35-42. 
 117.  Kivisakk P, Imitola J, Rasmussen S, et al. Localizing central nervous system 
immune surveillance: meningeal antigen-presenting cells activate T cells during 
experimental autoimmune encephalomyelitis. Ann. Neurol. 2009; 65: 457-469. 
 118.  Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated 
entry of TH-17 cells into the CNS through the choroid plexus is required for the 
initiation of EAE. Nat. Immunol. 2009; 10: 514-523. 
 119.  Engelhardt B and Ransohoff RM. The ins and outs of T-lymphocyte trafficking 
to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 
2005; 26: 485-495. 
 120.  Steffen BJ, Butcher EC and Engelhardt B. Evidence for involvement of ICAM-1 
and VCAM-1 in lymphocyte interaction with endothelium in experimental 
autoimmune encephalomyelitis in the central nervous system in the SJL/J 
mouse. Am. J. Pathol. 1994; 145: 189-201. 
 121.  Bullard DC, Hu X, Schoeb TR, et al. Intercellular adhesion molecule-1 
expression is required on multiple cell types for the development of 
experimental autoimmune encephalomyelitis. J. Immunol. 2007; 178: 851-857. 
 122.  Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental 
autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. 
Nature 1992; 356: 63-66. 
 123.  Cayrol R, Wosik K, Berard JL, et al. Activated leukocyte cell adhesion molecule 
promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 
2008; 9: 137-145. 
 60
 124.  Engelhardt B. The blood-central nervous system barriers actively control 
immune cell entry into the central nervous system. Curr. Pharm. Des 2008; 14: 
1555-1565. 
 125.  Wu C, Ivars F, Anderson P, et al. Endothelial basement membrane laminin 
alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat. Med. 
2009; 15: 519-527. 
 126.  Agrawal S, Anderson P, Durbeej M, et al. Dystroglycan is selectively cleaved at 
the parenchymal basement membrane at sites of leukocyte extravasation in 
experimental autoimmune encephalomyelitis. J. Exp. Med. 2006; 203: 1007-
1019. 
 127.  Hickey WF and Kimura H. Perivascular microglial cells of the CNS are bone 
marrow-derived and present antigen in vivo. Science 1988; 239: 290-292. 
 128.  Greter M, Heppner FL, Lemos MP, et al. Dendritic cells permit immune 
invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 2005; 
11: 328-334. 
 129.  Kawakami N, Lassmann S, Li Z, et al. The activation status of neuroantigen-
specific T cells in the target organ determines the clinical outcome of 
autoimmune encephalomyelitis. J. Exp. Med. 2004; 199: 185-197. 
 130.  Galea I, Bernardes-Silva M, Forse PA, et al. An antigen-specific pathway for 
CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007; 204: 2023-2030. 
 131.  Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends 
Neurosci. 1996; 19: 312-318. 
 132.  Charcot J. Histologie de la sclerose en plaques. Gazette des hopitaux, Paris 
1868; 41: 554-555. 
 133.  Medaer R. Does the history of multiple sclerosis go back as far as the 14th 
century? Acta Neurol. Scand. 1979; 60: 189-192. 
 134.  Holmoy T. A Norse contribution to the history of neurological diseases. Eur. 
Neurol. 2006; 55: 57-58. 
 135.  Hader WJ and Yee IM. Incidence and prevalence of multiple sclerosis in 
Saskatoon, Saskatchewan. Neurology 2007; 69: 1224-1229. 
 136.  Oksenberg JR, Baranzini SE, Sawcer S and Hauser SL. The genetics of multiple 
sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 2008; 9: 516-526. 
 137.  Ascherio A and Munger KL. Environmental risk factors for multiple sclerosis. 
Part I: the role of infection. Ann. Neurol. 2007; 61: 288-299. 
 138.  Ascherio A and Munger KL. Environmental risk factors for multiple sclerosis. 
Part II: Noninfectious factors. Ann. Neurol. 2007; 61: 504-513. 
 61
 139.  Miller D, Barkhof F, Montalban X, Thompson A and Filippi M. Clinically 
isolated syndromes suggestive of multiple sclerosis, part I: natural history, 
pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4: 281-288. 
 140.  McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria 
for multiple sclerosis: guidelines from the International Panel on the diagnosis of 
multiple sclerosis. Ann. Neurol. 2001; 50: 121-127. 
 141.  Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple 
sclerosis. Brain 1997; 120 ( Pt 6): 1085-1096. 
 142.  Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple 
sclerosis: a geographically based study. I. Clinical course and disability. Brain 
1989; 112 ( Pt 1): 133-146. 
 143.  Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA 
class II region in the association of the MHC region with multiple sclerosis. Nat. 
Genet. 2005; 37: 1108-1112. 
 144.  Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics 2008; 
60: 275-286. 
 145.  Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis 
identified by a genomewide study. N. Engl. J. Med. 2007; 357: 851-862. 
 146.  Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor 
alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007; 39: 
1108-1113. 
 147.  Ebers GC, Sadovnick AD and Risch NJ. A genetic basis for familial aggregation 
in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995; 377: 
150-151. 
 148.  Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and 
risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083-3088. 
 149.  Lunemann JD, Edwards N, Muraro PA, et al. Increased frequency and 
broadened specificity of latent EBV nuclear antigen-1-specific T cells in 
multiple sclerosis. Brain 2006; 129: 1493-1506. 
 150.  Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for 
TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 2002; 3: 940-943. 
 151.  Holmoy T, Kvale EO and Vartdal F. Cerebrospinal fluid CD4+ T cells from a 
multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic 
protein. J. Neurovirol. 2004; 10: 278-283. 
 152.  Jilek S, Schluep M, Meylan P, et al. Strong EBV-specific CD8+ T-cell response 
in patients with early multiple sclerosis. Brain 2008; 131: 1712-1721. 
 153.  Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus 
infection in the multiple sclerosis brain. J. Exp. Med. 2007; 204: 2899-2912. 
 62
 154.  Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001; 2: 
762-764. 
 155.  Holmoy T. Immunopathogenesis of multiple sclerosis: concepts and 
controversies. Acta Neurol. Scand. Suppl 2007; 187: 39-45. 
 156.  Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-
controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 
2006; 354: 899-910. 
 157.  Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a 
in early multiple sclerosis. N. Engl. J. Med. 2008; 359: 1786-1801. 
 158.  McFarland HF and Martin R. Multiple sclerosis: a complicated picture of 
autoimmunity. Nat. Immunol. 2007; 8: 913-919. 
 159.  Holmoy T, Vandvik B and Vartdal F. T cells from multiple sclerosis patients 
recognize immunoglobulin G from cerebrospinal fluid. Mult. Scler. 2003; 9: 
228-234. 
 160.  Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating 
lesions in established multiple sclerosis. Ann. Neurol. 2008; 63: 16-25. 
 161.  Barnett MH and Sutton I. The pathology of multiple sclerosis: a paradigm shift. 
Curr. Opin. Neurol. 2006; 19: 242-247. 
 162.  Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of 
multiple sclerosis. N. Engl. J. Med. 1998; 338: 278-285. 
 163.  Skulina C, Schmidt S, Dornmair K, et al. Multiple sclerosis: brain-infiltrating 
CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. 
Proc. Natl. Acad. Sci. U. S. A 2004; 101: 2428-2433. 
 164.  Junker A, Ivanidze J, Malotka J, et al. Multiple sclerosis: T-cell receptor 
expression in distinct brain regions. Brain 2007; 130: 2789-2799. 
 165.  Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central 
nervous system-infiltrating T cells and glial cells is associated with active 
disease in multiple sclerosis. Am. J. Pathol. 2008; 172: 146-155. 
 166.  Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote 
blood-brain barrier disruption and central nervous system inflammation. Nat. 
Med. 2007; 13: 1173-1175. 
 167.  Steinman L. A brief history of T(H)17, the first major revision in the 
T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007; 13: 
139-145. 
 168.  Oksenberg JR, Stuart S, Begovich AB, et al. Limited heterogeneity of 
rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis 
patients. Nature 1990; 345: 344-346. 
 63
 169.  Wucherpfennig KW, Newcombe J, Li H, et al. T cell receptor V alpha-V beta 
repertoire and cytokine gene expression in active multiple sclerosis lesions. J. 
Exp. Med. 1992; 175: 993-1002. 
 170.  Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CCR7 in multiple 
sclerosis: implications for CNS immunity. Ann. Neurol. 2004; 55: 627-638. 
 171.  Bar-Or A. The immunology of multiple sclerosis. Semin. Neurol. 2008; 28: 29-
45. 
 172.  Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the 
myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of 
a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000; 6: 1167-
1175. 
 173.  Montes M, Zhang X, Berthelot L, et al. Oligoclonal myelin-reactive T-cell 
infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. 
Clin. Immunol. 2009; 130: 133-144. 
 174.  Hafler DA, Benjamin DS, Burks J and Weiner HL. Myelin basic protein and 
proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell 
clones in multiple sclerosis and postinfectious encephalomyelitis. J. Immunol. 
1987; 139: 68-72. 
 175.  Schwartz M and Ziv Y. Immunity to self and self-maintenance: a unified theory 
of brain pathologies. Trends Immunol. 2008; 29: 211-219. 
 176.  van Noort JM, van Sechel AC, Bajramovic JJ, et al. The small heat-shock 
protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 
1995; 375: 798-801. 
 177.  Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory 
cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 
294: 1731-1735. 
 178.  Steinman L. New targets for treatment of multiple sclerosis. J. Neurol. Sci. 
2008; 274: 1-4. 
 179.  Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for 
antibody- and complement-mediated demyelination. Ann. Neurol. 1998; 43: 
465-471. 
 180.  Vandvik B, Vartdal F and Norrby E. Herpes simplex virus encephalitis: 
intrathecal synthesis of oligoclonal virus-specific IgG, IgA and IgM antibodies. 
J. Neurol. 1982; 228: 25-38. 
 181.  Vartdal F, Vandvik B and Norrby E. Intrathecal synthesis of virus-specific 
oligoclonal IgG, IgA and IgM antibodies in a case of varicella-zoster 
meningoencephalitis. J. Neurol. Sci. 1982; 57: 121-132. 
 64
 182.  Qin Y, Duquette P, Zhang Y, et al. Clonal expansion and somatic hypermutation 
of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. 
Invest 1998; 102: 1045-1050. 
 183.  Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B 
lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 
2000; 164: 2782-2789. 
 184.  Owens GP, Ritchie AM, Burgoon MP, et al. Single-cell repertoire analysis 
demonstrates that clonal expansion is a prominent feature of the B cell response 
in multiple sclerosis cerebrospinal fluid. J. Immunol. 2003; 171: 2725-2733. 
 185.  Owens GP, Kraus H, Burgoon MP, et al. Restricted use of VH4 germline 
segments in an acute multiple sclerosis brain. Ann. Neurol. 1998; 43: 236-243. 
 186.  Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal 
immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple 
sclerosis. Nat. Med. 2008; 14: 688-693. 
 187.  Baranzini SE, Jeong MC, Butunoi C, et al. B cell repertoire diversity and clonal 
expansion in multiple sclerosis brain lesions. J. Immunol. 1999; 163: 5133-5144. 
 188.  Qin Y, Duquette P, Zhang Y, et al. Intrathecal B-cell clonal expansion, an early 
sign of humoral immunity, in the cerebrospinal fluid of patients with clinically 
isolated syndrome suggestive of multiple sclerosis. Lab Invest 2003; 83: 1081-
1088. 
 189.  Monson NL, Brezinschek HP, Brezinschek RI, et al. Receptor revision and 
atypical mutational characteristics in clonally expanded B cells from the 
cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J. 
Neuroimmunol. 2005; 158: 170-181. 
 190.  Owens GP, Winges KM, Ritchie AM, et al. VH4 gene segments dominate the 
intrathecal humoral immune response in multiple sclerosis. J. Immunol. 2007; 
179: 6343-6351. 
 191.  Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B 
cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 
1667-1676. 
 192.  Owens GP, Bennett JL, Gilden DH and Burgoon MP. The B cell response in 
multiple sclerosis. Neurol. Res. 2006; 28: 236-244. 
 193.  O'Connor KC, Chitnis T, Griffin DE, et al. Myelin basic protein-reactive 
autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients 
are characterized by low-affinity interactions. J. Neuroimmunol. 2003; 136: 140-
148. 
 194.  Martino G, Olsson T, Fredrikson S, et al. Cells producing antibodies specific for 
myelin basic protein region 70-89 are predominant in cerebrospinal fluid from 
patients with multiple sclerosis. Eur. J. Immunol. 1991; 21: 2971-2976. 
 65
 195.  O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central 
nervous system tissue recognize myelin oligodendrocyte glycoprotein. J. 
Immunol. 2005; 175: 1974-1982. 
 196.  Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of 
clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. 
Med. 2003; 349: 139-145. 
 197.  Kuhle J, Lindberg RL, Regeniter A, et al. Antimyelin antibodies in clinically 
isolated syndromes correlate with inflammation in MRI and CSF. J. Neurol. 
2007; 254: 160-168. 
 198.  Lambracht-Washington D, O'Connor KC, Cameron EM, et al. Antigen 
specificity of clonally expanded and receptor edited cerebrospinal fluid B cells 
from patients with relapsing remitting MS. J. Neuroimmunol. 2007; 186: 164-
176. 
 199.  Vartdal F, Vandvik B and Norrby E. Viral and bacterial antibody responses in 
multiple sclerosis. Ann. Neurol. 1980; 8: 248-255. 
 200.  Luxton RW, Zeman A, Holzel H, et al. Affinity of antigen-specific IgG 
distinguishes multiple sclerosis from encephalitis. J. Neurol. Sci. 1995; 132: 11-
19. 
 201.  Vartdal F and Vandvik B. Multiple sclerosis. Electrofocused "bands" of 
oligoclonal CSF IgG do not carry antibody activity against measles, varicella-
zoster or rotaviruses. J. Neurol. Sci. 1982; 54: 99-107. 
 202.  Sindic CJ, Monteyne P and Laterre EC. The intrathecal synthesis of virus-
specific oligoclonal IgG in multiple sclerosis. J. Neuroimmunol. 1994; 54: 75-
80. 
 203.  Vartdal F and Vandvik B. Multiple sclerosis: subclasses of intrathecally 
synthesized IgG and measles and varicella zoster virus IgG antibodies. Clin. 
Exp. Immunol. 1983; 54: 641-647. 
 204.  Robinson-Agramonte M, Reiber H, Cabrera-Gomez JA and Galvizu R. 
Intrathecal polyspecific immune response to neurotropic viruses in multiple 
sclerosis: a comparative report from Cuban patients. Acta Neurol. Scand. 2007; 
115: 312-318. 
 205.  Skorstad G, Vandvik B, Vartdal F and Holmoy T. MS and clinically isolated 
syndromes: Shared specificity but diverging clonal patterns of virus-specific IgG 
antibodies produced in vivo and by CSF B cells in vitro. Eur. J. Neurol. 2009. 
PMID: 19469834 
 206.  Serafini B, Rosicarelli B, Magliozzi R, Stigliano E and Aloisi F. Detection of 
ectopic B-cell follicles with germinal centers in the meninges of patients with 
secondary progressive multiple sclerosis. Brain Pathol. 2004; 14: 164-174. 
 66
 207.  Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in 
chronic inflammation through expression of homing chemokines. J. Leukoc. 
Biol. 2001; 69: 331-339. 
 208.  Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation 
in the central nervous system of patients with multiple sclerosis. Proc. Natl. 
Acad. Sci. U. S. A 2004; 101: 11064-11069. 
 209.  Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in 
relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008; 358: 676-688. 
 210.  Cross AH, Stark JL, Lauber J, Ramsbottom MJ and Lyons JA. Rituximab 
reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. 
Neuroimmunol. 2006; 180: 63-70. 
 211.  Holmoy T and Vartdal F. The immunological basis for treatment of multiple 
sclerosis. Scand. J. Immunol. 2007; 66: 374-382. 
 212.  Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R and Sela M. Suppression of 
experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. 
Immunol. 1971; 1: 242-248. 
 213.  Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and 
improves disability in relapsing-remitting multiple sclerosis: results of a phase 
III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple 
Sclerosis Study Group. Neurology 1995; 45: 1268-1276. 
 214.  Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate 
(Copaxone) is well tolerated and maintains its clinical effect on multiple 
sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis 
Study Group. Neurology 1998; 50: 701-708. 
 215.  Fridkis-Hareli M and Strominger JL. Promiscuous binding of synthetic 
copolymer 1 to purified HLA-DR molecules. J. Immunol. 1998; 160: 4386-
4397. 
 216.  Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin 
basic protein and synthetic copolymer 1 to class II major histocompatibility 
complex molecules on living antigen-presenting cells--specificity and 
promiscuity. Proc. Natl. Acad. Sci. U. S. A 1994; 91: 4872-4876. 
 217.  Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T 
cell-mediated central nervous system autoimmune disease. Nat. Med. 2007; 13: 
935-943. 
 218.  Jung S, Siglienti I, Grauer O, et al. Induction of IL-10 in rat peritoneal 
macrophages and dendritic cells by glatiramer acetate. J. Neuroimmunol. 2004; 
148: 63-73. 
 219.  Li Q, Milo R, Panitch H, Swoveland P and Bever CT, Jr. Glatiramer acetate 
blocks the activation of THP-1 cells by interferon-gamma. Eur. J. Pharmacol. 
1998; 342: 303-310. 
 67
 220.  Vieira PL, Heystek HC, Wormmeester J, Wierenga EA and Kapsenberg ML. 
Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and 
increased IL-10 production through modulation of dendritic cells. J. Immunol. 
2003; 170: 4483-4488. 
 221.  Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte 
proliferation and enhances IL-5 and IL-13 production through modulation of 
monocyte-derived dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 
2006; 143: 357-362. 
 222.  Duda PW, Schmied MC, Cook SL, Krieger JI and Hafler DA. Glatiramer acetate 
(Copaxone) induces degenerate, Th2-polarized immune responses in patients 
with multiple sclerosis. J. Clin. Invest 2000; 105: 967-976. 
 223.  Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of 
copolymer-1- reactive T cell lines from treated and untreated subjects reveals 
cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. U. S. A 
2000; 97: 7452-7457. 
 224.  Ragheb S, Abramczyk S, Lisak D and Lisak R. Long-term therapy with 
glatiramer acetate in multiple sclerosis: effect on T-cells. Mult. Scler. 2001; 7: 
43-47. 
 225.  Chen M, Conway K, Johnson KP, Martin R and Dhib-Jalbut S. Sustained 
immunological effects of Glatiramer acetate in patients with multiple sclerosis 
treated for over 6 years. J. Neurol. Sci. 2002; 201: 71-77. 
 226.  Farina C, Then BF, Albrecht H, et al. Treatment of multiple sclerosis with 
Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and 
interferon-gamma response in blood cells. Brain 2001; 124: 705-719. 
 227.  Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) 
therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. 
Clin. Invest 2002; 109: 641-649. 
 228.  Aharoni R, Kayhan B, Eilam R, Sela M and Arnon R. Glatiramer acetate-
specific T cells in the brain express T helper 2/3 cytokines and brain-derived 
neurotrophic factor in situ. Proc. Natl. Acad. Sci. U. S. A 2003; 100: 14157-
14162. 
 229.  Aharoni R, Teitelbaum D, Sela M and Arnon R. Copolymer 1 induces T cells of 
the T helper type 2 that crossreact with myelin basic protein and suppress 
experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A 
1997; 94: 10821-10826. 
 230.  Aharoni R, Meshorer A, Sela M and Arnon R. Oral treatment of mice with 
copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 
cells in the central nervous system. J. Neuroimmunol. 2002; 126: 58-68. 
 
 68
 231.  Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the 
central nervous system of mice protected against experimental autoimmune 
encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. U. S. A 2000; 97: 
11472-11477. 
 232.  Aharoni R, Teitelbaum D, Sela M and Arnon R. Bystander suppression of 
experimental autoimmune encephalomyelitis by T cell lines and clones of the 
Th2 type induced by copolymer 1. J. Neuroimmunol. 1998; 91: 135-146. 
 233.  Aharoni R, Teitelbaum D, Arnon R and Sela M. Copolymer 1 acts against the 
immunodominant epitope 82-100 of myelin basic protein by T cell receptor 
antagonism in addition to major histocompatibility complex blocking. Proc. 
Natl. Acad. Sci. U. S. A 1999; 96: 634-639. 
 234.  Teitelbaum D, Fridkis-Hareli M, Arnon R and Sela M. Copolymer 1 inhibits 
chronic relapsing experimental allergic encephalomyelitis induced by 
proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T 
cell responses. J. Neuroimmunol. 1996; 64: 209-217. 
 235.  Ben-Nun A, Mendel I, Bakimer R, et al. The autoimmune reactivity to myelin 
oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially 
pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 1996; 
243: S14-S22. 
 236.  Burns J, Krasner LJ and Guerrero F. Human cellular immune response to 
copolymer I and myelin basic protein. Neurology 1986; 36: 92-94. 
 237.  Dabbert D, Rosner S, Kramer M, et al. Glatiramer acetate (copolymer-1)-
specific, human T cell lines: cytokine profile and suppression of T cell lines 
reactive against myelin basic protein. Neurosci. Lett. 2000; 289: 205-208. 
 238.  Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by 
glatiramer acetate. Neurology 2000; 55: 1704-1714. 
 239.  Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased 
response and crossreactivity with myelin basic protein in patients with MS. 
Mult. Scler. 2001; 7: 209-219. 
 240.  Schrempf W and Ziemssen T. Glatiramer acetate: mechanisms of action in 
multiple sclerosis. Autoimmun. Rev. 2007; 6: 469-475. 
 241.  Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O and Hohlfeld R. Glatiramer 
acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications 
for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 
125: 2381-2391. 
 242.  Chen M, Valenzuela RM and Dhib-Jalbut S. Glatiramer acetate-reactive T cells 
produce brain-derived neurotrophic factor. J. Neurol. Sci. 2003; 215: 37-44. 
 
 69
 243.  Aharoni R, Eilam R, Domev H, et al. The immunomodulator glatiramer acetate 
augments the expression of neurotrophic factors in brains of experimental 
autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A 2005; 102: 
19045-19050. 
 244.  Aharoni R, Herschkovitz A, Eilam R, et al. Demyelination arrest and 
remyelination induced by glatiramer acetate treatment of experimental 
autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A 2008; 105: 
11358-11363. 
 245.  Weber MS, Hohlfeld R and Zamvil SS. Mechanism of action of glatiramer 
acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007; 4: 647-653. 
 246.  Moreau T. Link of the mechanisms of action of glatiramer acetate to its long-
term clinical data. J. Neurol. Sci. 2009; 277 Suppl 1: S12-S15. 
 247.  Fitch F.W, Gajewski T.F. In vitro assays for mouse lymphocyte function. 
Current Protocols in Immunology.: Wiley, New York; 1997:3.13.1-3.13.4. 
 248.  Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell 
tumors by genetically targeted human T lymphocytes co-stimulated by CD80 
and interleukin-15. Nat. Med. 2003; 9: 279-286. 
 249.  Svenningsson A, Hansson GK, Andersen O, et al. Adhesion molecule 
expression on cerebrospinal fluid T lymphocytes: evidence for common 
recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal 
controls. Ann. Neurol. 1993; 34: 155-161. 
 250.  Svenningsson A, Andersen O, Edsbagge M and Stemme S. Lymphocyte 
phenotype and subset distribution in normal cerebrospinal fluid. J. 
Neuroimmunol. 1995; 63: 39-46. 
 251.  Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with 
early brain inflammation in multiple sclerosis. PLoS. ONE. 2008; 3: e2559. 
 252.  Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells 
dominate the T cell infiltrate in active multiple sclerosis lesions as shown by 
micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 
2000; 192: 393-404. 
 253.  Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, 
neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow 
cytometric assay. Blood 2004; 103: 4222-4231. 
 254.  Dallman MJ, Montgomery RA, Larsen CP, Wanders A and Wells AF. Cytokine 
gene expression: analysis using northern blotting, polymerase chain reaction and 
in situ hybridization. Immunol. Rev. 1991; 119: 163-179. 
 255.  Schuerwegh AJ, De Clerck LS, Bridts CH and Stevens WJ. Comparison of 
intracellular cytokine production with extracellular cytokine levels using two 
flow cytometric techniques. Cytometry B Clin. Cytom. 2003; 55: 52-58. 
 70
 256.  Kashima T, Tiu SN, Merrill JE, et al. Expression of oligodendrocyte-associated 
genes in cell lines derived from human gliomas and neuroblastomas. Cancer 
Res. 1993; 53: 170-175. 
 257.  Pauli G and Ludwig H. Increase of virus yields and releases of Borna disease 
virus from persistently infected cells. Virus Res. 1985; 2: 29-33. 
 258.  Buntinx M, Moreels M, Vandenabeele F, et al. Cytokine-induced cell death in 
human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and 
TNF-alpha on apoptosis. J. Neurosci. Res. 2004; 76: 834-845. 
 259.  Baumann N and Pham-Dinh D. Biology of oligodendrocyte and myelin in the 
mammalian central nervous system. Physiol Rev. 2001; 81: 871-927. 
 260.  Bruck W, Kuhlmann T and Stadelmann C. Remyelination in multiple sclerosis. 
J. Neurol. Sci. 2003; 206: 181-185. 
 261.  Williamson RA, Burgoon MP, Owens GP, et al. Anti-DNA antibodies are a 
major component of the intrathecal B cell response in multiple sclerosis. Proc. 
Natl. Acad. Sci. U. S. A 2001; 98: 1793-1798. 
 262.  Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell 
death. J. Immunol. Methods 1991; 145: 185-192. 
 263.  von Budingen HC, Harrer MD, Kuenzle S, Meier M and Goebels N. Clonally 
expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-
specific antibodies. Eur. J. Immunol. 2008; 38: 2014-2023. 
 264.  O'Connor KC, Chitnis T, Griffin DE, et al. Myelin basic protein-reactive 
autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients 
are characterized by low-affinity interactions. J. Neuroimmunol. 2003; 136: 140-
148. 
 265.  Butler JE, Ni L, Brown WR, et al. The immunochemistry of sandwich ELISAs--
VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl 
capture antibodies (CAbs) are denatured by passive adsorption. Mol. Immunol. 
1993; 30: 1165-1175. 
 266.  Molberg O, McAdam SN, Korner R, et al. Tissue transglutaminase selectively 
modifies gliadin peptides that are recognized by gut-derived T cells in celiac 
disease. Nat. Med. 1998; 4: 713-717. 
 267.  Lobel E, Riven-Kreitman R, Amselem A and Pinchasi I. Copolymer-1. Drugs 
Fut 1996; 21: 131-134. 
 268.  Kim HJ, Biernacki K, Prat A, Antel JP and Bar-Or A. Inflammatory potential 
and migratory capacities across human brain endothelial cells of distinct 
glatiramer acetate-reactive T cells generated in treated multiple sclerosis 
patients. Clin. Immunol. 2004; 111: 38-46. 
 71
 269.  Li PG, Oppezzi L, Seri M, et al. Repertoire breadth of human CD4+ T cells 
specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus 
toxoid (secondary antigens). Hum. Immunol. 1998; 59: 137-148. 
 270.  Kersh GJ and Allen PM. Essential flexibility in the T-cell recognition of antigen. 
Nature 1996; 380: 495-498. 
 271.  Hemmer B, Vergelli M, Pinilla C, Houghten R and Martin R. Probing 
degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. 
Today 1998; 19: 163-168. 
 272.  Arnon R and Aharoni R. Mechanism of action of glatiramer acetate in multiple 
sclerosis and its potential for the development of new applications. Proc. Natl. 
Acad. Sci. U. S. A 2004; 101 Suppl 2: 14593-14598. 
 273.  Zhang M, Chan CC, Vistica B, et al. Copolymer 1 inhibits experimental 
autoimmune uveoretinitis. J. Neuroimmunol. 2000; 103: 189-194. 
 274.  Smith-Jensen T, Burgoon MP, Anthony J, et al. Comparison of immunoglobulin 
G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven 
response. Neurology 2000; 54: 1227-1232. 
 275.  Hannestad K, Kristoffersen G and Briand JP. The T lymphocyte response to 
syngeneic lambda 2 light chain idiotopes. Significance of individual amino acids 
revealed by variant lambda 2 chains and idiotope-mimicking chemically 
synthesized peptides. Eur. J. Immunol. 1986; 16: 889-893. 
 276.  Guo W, Smith D, Guth A, Aviszus K and Wysocki LJ. T cell tolerance to 
germline-encoded antibody sequences in a lupus-prone mouse. J. Immunol. 
2005; 175: 2184-2190. 
 277.  Reitan SK and Hannestad K. The primary IgM antibody repertoire: a source of 
potent idiotype immunogens. Eur. J. Immunol. 2001; 31: 2143-2153. 
 278.  Vanderlugt CL and Miller SD. Epitope spreading in immune-mediated diseases: 
implications for immunotherapy. Nat. Rev. Immunol. 2002; 2: 85-95. 
 279.  Singh RR, Hahn BH, Tsao BP and Ebling FM. Evidence for multiple 
mechanisms of polyclonal T cell activation in murine lupus. J. Clin. Invest 1998; 
102: 1841-1849. 
 280.  Coyle PK. Detection and isolation of immune complexes in multiple sclerosis 
cerebrospinal fluid. J. Neuroimmunol. 1987; 15: 97-107. 
 281.  Ulvestad E, Williams K, Vedeler C, et al. Reactive microglia in multiple 
sclerosis lesions have an increased expression of receptors for the Fc part of IgG. 
J. Neurol. Sci. 1994; 121: 125-131. 
 282.  Kelsoe G. Life and death in germinal centers (redux). Immunity. 1996; 4: 107-
111. 
 72
 283.  Zhang X, Smith DS, Guth A and Wysocki LJ. A receptor presentation 
hypothesis for T cell help that recruits autoreactive B cells. J. Immunol. 2001; 
166: 1562-1571. 
 284.  Cowell LG, Kim HJ, Humaljoki T, Berek C and Kepler TB. Enhanced 
evolvability in immunoglobulin V genes under somatic hypermutation. J. Mol. 
Evol. 1999; 49: 23-26. 
 285.  Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis 
lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000; 
47: 707-717. 
 286.  Barnett MH and Prineas JW. Relapsing and remitting multiple sclerosis: 
pathology of the newly forming lesion. Ann. Neurol. 2004; 55: 458-468. 
 287.  Cannella B, Gaupp S, Omari KM and Raine CS. Multiple sclerosis: death 
receptor expression and oligodendrocyte apoptosis in established lesions. J. 
Neuroimmunol. 2007; 188: 128-137. 
 288.  Smorodchenko A, Wuerfel J, Pohl EE, et al. CNS-irrelevant T-cells enter the 
brain, cause blood-brain barrier disruption but no glial pathology. Eur. J. 
Neurosci. 2007; 26: 1387-1398. 
 289.  Lundin KU, Screpanti V, Omholt H, et al. CD4+ T cells kill Id+ B-lymphoma 
cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. 
Cancer Immunol. Immunother. 2004; 53: 1135-1145. 
 290.  Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune 
response mediated by CD4+ T cells. Immunity. 2005; 22: 371-383. 
 291.  Zangani M, Carlsen H, Kielland A, et al. Tracking early autoimmune disease by 
bioluminescent imaging of NF-kappaB activation reveals pathology in multiple 
organ systems. Am. J. Pathol. 2009; 174: 1358-1367. 
 292.  Carlsen H, Moskaug JO, Fromm SH and Blomhoff R. In vivo imaging of NF-
kappa B activity. J. Immunol. 2002; 168: 1441-1446. 
 
 
 73
8. ERRATUM 
 
Paper III: 
Hestvik AL, Vartdal F, Fredriksen AB, Thompson KM, Kvale EO, Skorstad G, Bogen 
B and Holmoy T. T cells from multiple sclerosis patients recognize multiple epitopes on 
self-IgG. Scand J Immunol. 2007; 66: 393-401: 
 
Page 398; Figure 6: A = A + C 
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